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ABSTRACT
Protein disulfide isomerase (PDI) is involved in isomerization, reduction and oxidation of 
disulfide bonds. Recent studies from our lab showed that cell-surface PDI is also 
involved in transport of nitric oxide (»NO) inside the cells. *NO is a small signaling 
molecule involved in many cellular processes.
We have utilized S-nitrosoglutathione (GSNO) as a substrate for PDI in order to 
characterize its denitrosation activity. Our results suggested that final product of PDI- 
mediated GSNO denitrosation is »NO. We have shown that PDI stores *NO released 
from GSNO, probably in the form of N 2O3 and can transfer it to intra- and intermolecular 
thiols. Our findings suggest that PDI could have an important role in both efflux and 
influx of S-nitrosothiols (RSNO)-bound *NO.
We have shown that platelet surface PDI (psPDI) was able to mediate GSNO 
denitrosation thus inhibiting platelet aggregation. Animal models of the pre-diabetic state 
indicated that psPDI activity was diminished, platelet ROS production and aggregation 
rates were enhanced compared to controls. Treatment of animals with rosuvastatin, an 
inhibitor of HMG-CoA reductase, showed efficacy in normalizing activities monitored in 
this animal model of diabetes. Monitoring the dynamic thiol and disulfide states provides 
an insight for evaluating PDI-dependent processes. We have shown, using ICAT- 
MALDI technology, that the PDI a domain active site thiols undergo spontaneous 
oxidation, while the a ’ domain thiols are present in an oxidized state.
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The presence of PDI on the ghost membranes of RBC suggested that it may play a role in 
NO-efflux from RBC. We have shown that ghost-associated PDI disulfide reductase 
activity is inhibited in the presence of NO donors, accompanied by a decrease in thiol 
concentration, due to the S-nitrosation of PDI active site thiols. These findings strongly 
suggest the NO transport in RBC could be mediated by PDI present on the ghost 
membranes.
We have shown that iron(III) is a potent inhibitor of caspase-3 activity. Our results 
suggest that PDI is capable of activating caspase-3 inhibited by iron(III), probably by 
formation of iron-sulfur complexes through its active site thiols. We propose a 
physiological role for Fe(III) and PDI dependent caspase-3 activation in the process 
regulating apoptosis.
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CHAPTER 1
Introduction to Protein Disulfide Isomerase and Nitric Oxide
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2
1.1 Protein Disulfide Isomerase
Protein disulfide isomerase (PDI) was First isolated from bovine liver and characterized 
by Anfmsen in the 1960’s (Goldberger et al., 1963; DeLorenzo et al., 1966). Its primary 
location was found to be the lumen of the rough endoplasmic reticulum (ER) where it 
assists in the folding of newly synthesized proteins by performing a series of disulfide 
isomerization reactions. PDI has been found widely distributed across eukaryotic cells 
where it performs a variety of functions (Turano et al., 2002).
1.1.1 Structure and classification
PDI belongs to the PDI-like family of proteins and all of them are characterized by the 
multidomain arrangement. Each domain resembles the typical thioredoxin fold which is 
formed by the specific sequence of a-helixes and p-strands: 
P l-a l-p 2 -a 2 -p 3 -a 3 -p 4 -p 5 -a 4  (Kemmink et a l, 1997; Ferrari et al., 1998). PDI is 
-55 kDa protein consisting of 5 domains, as shown in Figure 1.1 (Darby et al., 1996). 
Two redox active domains, a and a’ contain the active site sequence CGHC that performs 
reduction and oxidation reactions. Domains b and b’ lack the active site, but still 
resemble the thioredoxin fold (Kemmink et al., 1999). Domain c consists of highly 
negatively charged sequences that contribute to the low affinity, high capacity calcium 
binding properties of PDI (Macer and Koch, 1988), and the KDEL sequence for retention 
in the ER (Kemmink et al., 1997).
Reproduced  with permission of the copyright owner. Further reproduction prohibited without permission.
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CGHC
Figure 1.1: Domain organization of PDI (Darby etal, 1996)
In the recent review by Ellgaard and Ruddock (Ellgaard and Ruddock, 2005), the human 
PDI-like family of proteins consists of 17 members all of which contain at least one 
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Figure 1.2: Overview of human PDI family
The green squares represent the active site domains (a and a’), the catalytically inactive 
domains are shown in yellow and pink (b and b’, respectively), and the linker region 
between b’ and a’ is shown in blue.
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The overall role of different domains of PDI remained a mystery until the structures of 
individual domains (Kemmink et a l, 1995, 1996) were solved and most recently, the 
overall structure of yeast PDI was determined (Tian et al., 2006). Initial structural 
studies of individual domains of PDI by Kemmink revealed that a and b domains share 
highly conserved secondary structure elements despite their low primary sequence 
identity (11%) (Kemmink et al, 1999). Besides the absence of the active site CGHC, b 
domain has (34 sheet antiparallel to the others (Figure 1.3) 
f-'
Figure 1.3: MOLSCRIPT representation of PDI a-domain (a) and PDI-b-domain (b)
Adapted form Kemmink et al (1997) with the permission from Elsevier.
The redox activity of PDI is due to reactivity of its active site cysteines in CGHC peptide,
nearby histidine imidazole group (Ferrari and Soling, 1999). Therefore, the disulfide
especially its N-terminal Cys which has a pKa of 4.5 and is partially stabilized by the
Reproduced  with permission of the copyright owner. Further reproduction prohibited without permission.
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form of the protein is relatively unstable as compared to thioredoxin and results in 
oxidative rather than reductive function (Kortemme et al,. 1996, Freedman et al., 1995). 
Based on these early single domain studies, it was proposed that the other domains a’ and 
b’ should resemble the a and b domains, respectively, but the overall domain 
arrangement was unknown until the crystal structure of yeast PDI was determined. Since 
the yeast and mammalian PDI share a high degree of primary structure and domain 
arrangement, it seems very likely that they will share the same architecture (Tian et al., 
2006).
1.1.2 Understanding the structure and function of PDI
In the absence of overall mammalian PDI structure, initial research of understanding the 
significance of individual domains was performed by studying multidomain constructs. 
Darby and coworkers (Darby et a l, 1998) observed that for the disulfide bond 
isomerization, the absence of b’ and a’ domains totally inhibited PDI activity, thereby 
suggesting that these two domains play a crucial role in substrate binding. Disulfide 
bond formation and reduction was significantly decreased in the absence of a full PDI 
construct, suggesting that the overall multidomain architecture of PDI has evolved in this 
way in order to achieve its versatile catalytic repertoire enabled though PDI substrate 
interactions.
The crystal structure of the yeast PDI and its individual domains is shown in Figure 1.4.
R eproduced  with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 1.4: Overall structure of yeast PDI (PDB 2B5E)
A) Ribbon diagram o f PDI. B) Ribbon diagram of individual domains.
(Tian et al., 2006) with the permission from Elsevier.
As shown in Figure 1.4 (a), PDI resembles the letter “U”, with the b and b’ domains at 
the base and the a and a’ domains at the ends of “U”. Each of the domains appears to 
have a typical thioredoxin fold with minor variations. For example, b domain does not 
contain the third a  helix and its second helix is shorter while the b’ domain has an 
additional short helix and lacks the first (3 sheet. The four domains are arranged in an 
asymmetrical geometry which allows domain a to be in contact with both the b and b’ 
domains, while a’ interacts with b’ domain only. The active sites on the a and a’ 
domains point towards each other but are separated by the large cleft, although the 
interaction may be possible since a and a’ domains are more flexible with respect to the 
rigid base consisting of b and b’ domains.
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a) Active site a and a’ domains
Even though the a and a’ domains share a high structural homology, there are a few 
significant differences observed in yeast PDI. First of all, the redox state of two active 
site domains are different in a way that a domain active site was found to be in its 
oxidized form while a’ domain active site was detected in its reduced form. This can be 
explained by the corresponding standard redox potentials of -188 mV for the a domain 
and -152 mV for the a’ domain. If these values are compared with the strongest oxidant 
in the thioredoxin family, DsbA that has the redox potential of -120 mV (Zapun et a l, 
1993) and strongest reductant thioredoxin with redox potential o f -270 mV (Aslund et al., 
1997; Moore et al., 1964), it may be speculated that in yeast PDI, the active site of the a 
domain will be mainly in its oxidized form while the active site of the a’ domain will be 
reduced.
Another difference lies in the location of tryptophan residue located immediately before 
each active site cysteine. In the a domain, W6o seems to be fixed at its location while 
W405 of a’ domain is highly mobile. As a result of this, the C406 of the a’ domain is more 
exposed to the solvent than C6 i, hence making the active site of a’ domain more 
accessible.
b) Hydrophobic b and b’ domains
The structure of PDI reveals several surface exposed hydrophobic patches. Two of them 
surround the active sites in a and a’ domains, while b and b’ domains each have one 
exposed hydrophobic patch at the relatively same position. As a consequence of this, the 
continuous hydrophobic surface is formed which plays a crucial role in the interaction
Reproduced  with permission of the copyright owner. Further reproduction prohibited without permission.
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between PDI and its substrates. Retrospectively, the opening between a and a’ domain 
and the hydrophobic pocket in b’ domain is large enough to accommodate a folded 
protein of about 100 residues. This study is in agreement with the earlier observations 
made by Klappa and coworkers (Klappa et al., 1998) where they reported the presence of 
highly hydrophobic pockets in the b’ domain and recognized it as the primary peptide 
binding site. Although it could be speculated that b domain could share the peptide 
binding properties of b’ domain, the studies using mutants bb’a’c and b’a’c showed that 
the b’ domain plays a role in the refolding of proteins while b domain may influence the 
refolding rates in selected cases (Tian et al., 2006)
1.1.3 Multifunctional aspects of PDI
PDI is a multifunctional enzyme involved in isomerization, reduction, oxidation, 
chaperone and other activities which will be described in the following sections.
1.1.3.1 Isomerazation, reduction and oxidation
One of the first studied functions of PDI was the folding of newly synthesized proteins in 
the ER. Since the concentrations of PDI in the ER is approximately 0.8% of the total 
cellular protein (Freedman et al., 1994) and it interacts with a broad group of peptides 
(Noiva, 1994), it can be speculated that PDI is one of the most important enzymes for the 
correct assembly of proteins in the ER.
The major oxidizing and reducing power in the ER is thought to be combination of 
glutathione (GSH) and glutathione disulfide (GSSG). The ER is considered to be more
Reproduced  with permission of the copyright owner. Further reproduction prohibited without permission.
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oxidative environment since the ratio of GSH to GSSG is close to 2:1, while in the 
cytoplasm this ratio is more reducing and it varies from 20:1 to 100:1 (Noiva, 1994). 
Oxidizing equivalents in the ER come from an additional source which is the Erol 
protein that is proposed to form a mixed disulfide with the reduced PDI thereby oxidizing 
it. The Erol FAD moiety would essentially allow for the constant electron transfer to O2 
thus completing the redox circle (Ellgaard, 2004).
The mechanism for the role of PDI in isomerization, reduction and oxidation is shown in 
Figure 1.5. The first step in rearrangement of misfolded disulfide bonds involves 
nucleophilic attack of the N-terminal cysteine in CGHC active site of PDI which results 
in the formation of a mixed disulfide between PDI and its substrate. The isomerization is 
completed by the attack of the second cysteine of PDI, which breaks a mixed disulfide 
bond, leaving PDI in its reduced state and the properly folded substrate. In the case 
where isomerization fails to proceed to completion, a series of reduction and oxidation 
reactions take place, until the substrate folds into the proper conformation and resists 
further attack by PDI (Schwaller et al., 2003).
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Figure 1.5: Isomerization, reduction and oxidation of PDI (Schwaller et a l 2003)










A protein is referred to as a chaperone if it is able to assist unfolded or misfolded proteins 
to attain the native state by providing a protective microenvironment which decreases the 
chance of aggregation and precipitation. PDI is a chaperone with a wide range of 
substrates. It chaperones proteins that contain disulfide bonds such as lysozyme (Puig 
and Gilbert, 1994; Hayano et a l, 1996), and proteins which lack disulfide bonds such as 
acidic phospholipase A2 (Yao et al., 1997), glyceraldehyde-3-phosphate dehydrogenase 
(Cai et al., 1994) and rhodanase (Song and Wang, 1995) as shown by in vitro refolding 
studies. The ability of PDI to act as a chaperone is shown to be independent of its 
isomerase activity and does not involve its active site CGHC sequence. Previous studies 
have shown that the acidic domain c plays a crucial role in PDI chaperone activity since 
the mutated PDI lacking c domain showed no chaperone activity (Dai and Wang, 1997).
1.1.3.3 Subunit of other enzymes
a) Prolyl 4-Hydoxylase
Prolyl 4 -hydroxylase (P4H) is an enzyme located in the ER where it catalyzes the 
hydroxylation of proline residues of newly synthesized procollagen polypeptides 
(Kivirikko et a l, 1989). It consists of two a  and two P subunits, with a  subunits being 
catalytically active. Protein sequencing and DNA analysis of P subunit of P4H suggested 
that this subunit is identical to PDI (Bulleid, 1993). There are several different proposed 
roles of PDI as a part of P4H. It was initially believed that the active site of PDI may 
play a role in the various redox steps of the hydroxylation reaction, or it may act as a
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retention signal for P4H considering that P4H lacks the retention sequence at its C- 
terminus (Bassuk et a l, 1989) and finally it may provide a molecular support by keeping 
the enzyme in its soluble form, since earlier in vitro studies have shown that the a  
subunits of P4H aggregate when they are dissociated from the (3 subunits (Tuderman et 
al, 1975).
b) Microsomal Triglyceride Transfer Protein
Microsomal triglyceride transfer protein (MTP) is a heterodimer consisting of two 
subunits (58 kDa and 8 8  kDa) and catalyzes the transfer of triglycerides into lipoproteins. 
The 58 kDa subunit has been characterized as PDI (Wetterau et al., 1990), and here it 
keeps the MTP complex in a soluble form since the removal of the smaller subunit results 
in the irreversible aggregation and inactivation (Wetterau et al, 1991). It is interesting 
that the MTP has very little PDI isomerase activity (Wetterau et al., 1990), suggesting 
that the active site of PDI is either inaccessible or unreactive.
1.1.3.4 Other functions of PDI
Narindrasorasak and coworkers recently reported that PDI is capable of binding copper 
up to 4-10 mols of Cu(I) per mole of PDI (Narindrasorasak et al., 2003). The binding of 
copper is thought to take place though the CGHC of a domain of PDI as it remarkably 
resembles the fold of Atoxl, which is a copper chaperone. This binding results in the 
formation of PDI tetramer. It has been hypothesized that this copper-bound PDI may act 
as the copper donor for copper containing proteins during de novo synthesis or as a 
copper chelator in the cells during the binding of copper in copper toxicity. Similarly,
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PDI has been shown to bind to zinc (Zn2+) (Solovyov and Gilbert, 2004) through the 
coordination with cysteines in PDI a, a’ and b’ domains, resulting in dimer formation and 
higher order oligomers and aggregates. Surprisingly, while Zn2+usually coordinates with 
four ligands, the site directed mutagenesis studies showed that for PDI only one cysteine 
in the active site (CGHS) is necessary for PDI to form a dimer as efficiently as the wild 
type. Therefore, it has been proposed that PDI may serve as a zinc chelator and protects 
the cells from divalent ion toxicity. However, it is of a great importance to mention that 
while PDI is acting as a chelator, as in the cases of copper or zinc, its enzymatic activity 
significantly decreases which may cause a dysfunction in proper protein folding in the 
ER.
1.1.4 Cell surface protein disulfide isomerase
Besides its primary location in the ER, PDI is also found on the cell surface (csPDI) 
where it binds though electrostatic interactions (Terada et al., 1995). Although PDI 
should theoretically remain in the ER, since it contains the ER retention sequence 
(KDEL), there are a couple of different hypotheses proposed for PDFs ability to escape 
the ER. Initially, it was believed that PDI may be able to escape the ER by saturation of 
the KDEL sequence, which is known to be involved in peptide binding (Bulleid, 1993). 
Another mechanism proposes that PDI, when associated with other secretory proteins, 
may escape the ER and localize itself on the surface (Johnson et al., 2001). Cell surface 
PDI has been found in the variety of cells including platelets (Chen et al., 1995), 
leukocytes (Bennett, et al., 2000), hepatocytes (Terada et al., 1995), endothelial cells
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(Hotchkiss et ah, 1998) and pancreatic cells (Yoshimori et al., 1990) where it plays a role 
in a variety of physiological conditions.
a) HIV entry and csPDI
The entry of HIV into human cells requires protein interaction between the viral envelope 
glycoprotein gpl20 and the primary receptor CD4 of the host cell (Berger et ah, 1999). It 
was found that CD4 binds to csPDI resulting in a CD4-PDI-gpl20 (Figure 1.6) complex 
that allows PDI to access and reduce gpl20 disulfides leading to the gpl20 









Figure 1.6: PDI mediated HIV entry (Ryser and Fluckiger, 2005).
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Based on these findings, a novel approach for targeting HIV entry has been proposed and 
it involves three possibilities. One is to target the activity of PDI, which is necessary for 
disulfide bond shuffling. Unfortunately, since PDI is a crucial enzyme for various 
cellular processes as described in previous sections, targeting PDI activity may not be the 
most suitable approach. Instead, current research is concentrating on the binding sites 
between PDI-CD4 as well as PDI-gpl20, which seems to be a more appropriate target 
(Figure 1.6).
b) Cell adhesion
Cell surface PDI plays a role in cell adhesion by shuffling surface thiols and disulfides, 
thereby promoting adhesion or dissociation between various cells. For example, PDI 
associated with the platelet surface is found to promote platelet aggregation through 





Figure 1.7: csPDI mediated platelet aggregation (Essex, 2004)
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As shown in Figure 1.7, the platelet fibrinogen receptor (alip3, pink and yellow) is in its 
reduced state under resting conditions. The first conformational change results from 
agonist-induced stimulation and initiates fibrinogen (blue) interaction with alip3 (a). 
PDI (light blue) catalyzes disulfide exchange of alip3 (b, c) that subsequently leads to a 
high affinity conformation state which results in platelet aggregation.
Another example is the role of csPDI in the regulation of L-selectin shedding. L-selectin 
is the membrane protein that mediates the recruitment of leukocytes to inflammatory sites 
(Springer, 1995). During leukocyte activation, L-selectin undergoes proteolytic cleavage 
which results in its release from the cell surface thus disabling leukocytes from the L- 
selectin dependent cell interaction (Tedder et al., 1995). The idea of csPDI playing a role 
in cell adhesion came from the study of Bennett and coworkers (Bennett, 2000), which 
showed that the vicinal dithiol specific blocker phenyl arsine oxide (PAO) was able to 
induce L-selectin shedding. Further evidence supporting PDI involvement in L-selectin 
shedding was obtained by using bacitracin, a common PDI inhibitor, and PDI specific 
antibodies, both of which induced L-selectin shedding.
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L-selectin L-selectin
Figure 1.8: csPDI role in L-selectin shedding (Bennette, 2000)
Figure 1.8 A shows that csPDI maintains L-selectin in its reduced state which sustains its 
non-cleavable conformation, thereby resulting in its inaccessibility to the proteolytic 
action of sheddase (lavender). However, upon blocking PDI active site cysteines with 
PAO, L-selectin changes its conformation and becomes accessible to the sheddase 
proteolytic action.
c) PDI-mediated NO release
Besides performing disulfide exchange reactions on the cell surface, Ramachandran and 
coworkers showed that PDI is also involved in generation of nitric oxide (NO) from 
S-nitrosothiol molecules (RSNO) (Ramachandran et ah, 2001).
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Figure 1.9: The role of csPDI in intracellular nitrosation (Ramachandran et al,
2001)
This study provided the first evidence that csPDI is able to catalyze NO release from 
RSNOs (Figure 1.9), followed by its accumulation in the membrane where it reacts 
rapidly with 0 2 (Liu et al., 1998) to form N2 0 3 at the membrane-cytosol interface which, 
in turn, can nitrosate intracellular thiols (Nedospasov et al., 2000).
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1.2 Nitric oxide
Nitric oxide (*NO), a diatomic free radical gas molecule, is one of the most ubiquitous 
substances found to be involved in a variety of physiological and pathophysiological 
processes. During the early 1980s, *NO was identified from what was believed to be the 
endothelium-derived relaxing factor (EDRF) by several independent research groups 
(Ignarro, Moncada and Furchgott) for which were awarded the Nobel Prize in physiology 
and medicine in 1998. Due to its great importance in the field o f science, extensive 
research about *NO has been conducted in the last two decades.
1.2.1 Chemistry and Biology
In order to understand the behavior, nature and reactivity of *NO, the basic principles 
governing the chemistry and biology of ’NO must be understood. The following sections 
will give a detailed insight into the chemistry and biology of *NO.
1.2.1.1 Chemical Properties of Nitric Oxide
Nitric oxide is a colorless gas at the room pressure and temperature with a maximum 
solubility in water of approximately 2 mM (Venkataraman, et al., 2000). The reactivity 
of *NO can be depicted by simply looking at its Lewis dot diagram (Figure 1.10) where 
•NO has one unpaired electron and thus is considered to be a free radical.
• N *  +  * 0 -•  • •
•  •
Figure 1.10: Lewis dot structure of •NO
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The molecular orbital diagram (Figure 1.11) (Stanbury, 1989) of *NO consists of a cts 
bonding orbital and corresponding os* antibonding orbital, two n x,y bonding orbitals and 
slightly higher in energy a z bonding orbital, two 7tx,y* antibonding orbitals and a high 
energy a z* antibonding orbital. Therefore, *NO is a paramagnetic molecule with an 
unpaired electron in a tc* antibonding orbital. The stability of *NO as a monomer comes 
from the fact that *NO has a bond order of 2.5 and formation of a dimer (0=N-N=0) 
would give the overall bond order of 5, thus there is no net gain in overall bonding and 




N atomic orbitals O atomic orbitals
Figure 1.11: Molecular orbital diagram of »NO (Stanbury, 1989)
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As described in the above paragraph, *NO is a free radical and based on its unique 
chemistry, it can undergo a variety of redox reactions generating new nitric oxide species. 
•NO can undergo reduction by accepting an electron to give a nitroxide species (N 0‘), or 
oxidation by losing an electron resulting in nitrosonium (NO+). In the presence of 
molecular oxygen (O2), ‘NO undergoes a series of reactions to form higher nitric oxide 
species. Formation of nitrogen dioxide (‘NC^) involves reactions (1-3) and consumes 2 
equivalents of *NO. Once »N0 2  is formed (3), it can react via reaction (4) with another 
•NO2 molecule to form dinitrogen tetroxide (N2O4). Another possibility involves 
combination of "NC^ and »NO to give a potent nitrosating agent (Gobert et al., 1999) 
dinitrogen trioxide (N2O3) as in reaction (5).
•N0 + 0 2 - * -0 0 N 0  (1)
•OONO + *NO -> ONOONO (2)
ONOONO -* 2 *N02 (3)
•N02 + *N02 -> N2 O4  (4)
•N02 + -NO -► N 2 0 3 (5)
1.2.1.2 Biological Properties of Nitric Oxide
Physiologically, *NO is involved in a great variety of cellular processes including roles in 
vasculature, immune response and neurotransmission (Moncada et al., 1991). However, 
the in vivo reactivity of *NO is determined by its chemical properties, and for 
simplification purposes, the *NO reactions are divided into two categories: i) direct 
effects, and ii) indirect effects.
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i) Direct effects
Direct effects involve chemical reactions of »NO with its target which is usually a heme- 
containing protein. The summary of the reactions depicting direct effects is shown in 
Figure 1.12.
NO
NO + Hb(02) —> metHb Fe(IV)=0 + NO —> Fe(II) LOO* + NO—♦ LOONO
1. Guanylate cyclase activation
2. Reversible inhibition of Cyt P450










Consumption of NO Limits formation of oxidants
and cellular oxidative stress
4. Activation o f Hemoxygenase
5. Aconitase
6. Inhibition o f Catalase
7. Reversible inhinibition o f Cyt c 
oxidase
8. Binding to IRE; stimulation of 
Transferrin receptor; inhibition of 
Ferritin
Figure 1.12: Direct effects of nitric oxide
The most important reaction of *NO involves reaction with iron centers of the heme. In 
some cases, this leads to the significant activation of the target enzyme, while in others, 
to the reversible inhibition. The most studied nitrosylation of the heme resulting in the 
enzyme activation is most likely soluble guanylate cyclase (GC) (Murad, 1994). Upon 
•NO binding to the heme of GC, the position of iron within porphorin ring shifts in such a 
way that the five-coordinate nitrosyl complex becomes favoured (Stone and Marietta, 
1994). This leads to a significant GC activation by *NO, with EC50 of 100 nM,
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(Forstermann and Ishii, 1996) resulting in the conversion of guanosine triphosphate 
(GTP) to cyclic guanosine monophosphate (cGMP) which in turn initiates a signaling 
cascade responsible for smooth muscle relaxation. On the contrary, nitric oxide is able to 
reversibly inhibit monooxygenases such as cytochrome P-450 (Wink et al., 1993). Here, 
the same principle follows with *NO binding to the heme iron, causing a conformational 
change and displacement of O2 that is required to facilitate oxidative chemistry.
ii) Indirect Effects
Indirect effects involve species derived from *NO; therefore it requires a higher 
concentration of *NO than for direct effects, as well as a supply of O2 or superoxide (CV)- 




















Figure 1.13: Indirect effects of nitric oxide
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As shown in Figure 1.13, indirect effect of *NO can be subdivided into two classes. The 
first one involves nitrosative stress which mainly affects primary amines and thiols, while 
the second one, oxidative stress may result in the modification of variety of 
macromolecules including DNA, tyrosine residues in proteins and lipids. Therefore, 
indirect effects are usually associated with a variety of pathophysiological conditions, and 
this is thought to be due to the presence of higher nitrogen oxide species (Miranda et al., 
2000).
1.2.2 Endogenous Nitric Oxide
Enzymes involved in endogenous *NO production are called nitric oxide synthases 
(NOS). There are three isoforms of NOS enzymes and all of them catalyze the five 
electron oxidation of L-arginine to yield one mole of nitric oxide and citrulline as shown 
in Figure 1.14 with the overall reaction consuming 1.5 moles of NADPH and two moles 
of O2 .
+




L-arginine Nw- hydroxyarginine Citrulline
Figure 1.14: »NO synthesis from L-arginine (Hevel and Marietta, 1994)
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Although the above reaction appears simple, there are numerous cofactors that play a 
crucial role in electron transport. Three isoforms of the NOS family of proteins include: 
neuronal NOS (nNOS or NOS 1), which is involved in neurotransmission and long-term 
potentiation; inducible NOS (iNOS or NOS 2), which regulates immune response; and 
endothelial NOS (eNOS or NOS 3), which mediates smooth muscle relaxation. Each 
isoform exists as a homodimer and consists of the C-terminus reductase domain which 
includes binding sites for calmodulin (CaM), flavine mononucleotide (FMN), flavin 
adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate (NADPH). 
The N-terminus oxygenase domain contains a heme, tetrahydrobiopterin (BH4) and an 
arginine binding site (Figure 1.15).
Oxygenase domain Reductase domain
_A _r~ >1 r >1




NH 2—  H4B/Fe/Arg CaM FMN FAD NADPH — COOH
Endothelial NOS NH2- 
133 kDa
H4B/Fe/Arg CaM FMN FAD NADPH — COOH
Figure 1.15: Domain organization of three NOS isoforms (Ignarro, 2000)
The presence of calcium (Ca2+) initiates calmodulin binding which in turn activates the 
reductase domain allowing for the electron transfer from NADPH to FAD and FMN in
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the reductase domain to the iron heme and BH4 in the oxygenase domain (Alderton et al., 
2001). iNOS has a tightly bound CaM and Ca2+ (Abu-Soud and Stuehr, 1993) and 
produces large amounts of nitric oxide, while nNOS and eNOS produce relatively small 
amounts of »NO and require Ca2+ and calmodulin for activation.
It is now well recognized that FAD and FMN are involved in electron shuffling from 
NADPH, while the domain containing the iron heme is responsible for carrying out redox 
reactions and L-arginine binding, the role of BH4 is still controversial to some extent. 
BH4 plays a role in both steps of *NO synthesis from L-arginine (Figure 1.14), as shown 
by the decrease in nitric oxide production during BH4 depletion in iNOS and eNOS 
(Kinoshita et al., 1997). Also, it has been shown that BH4 was able to stabilize nNOS 
dimer formation, this was not apparent in eNOS (Klatt et al., 1995). Therefore, it appears 
that the function of BH4 varies in different NOS iso forms, although it is an unconditional 
requirement for »NO synthesis. BH4 is now a well recognized 1-electron donor to the 
oxyferrous complex of NOS heme and is also an integral part of heme protonation 
required for *NO synthesis (Gorren et al., 2006).
1.2.3 S-nitrosothiols
S-nitrosothiols (RSNOs) are a physiological cellular source of nitric oxide. Since *NO is 
a relatively short lived molecule, formation of RSNO has been shown to prolong the half 
life of *NO (Girard and Potier, 1993). Also, RSNOs may serve as a transport and storage 
system under physiological conditions, and provide the same biochemical effects as *NO.
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1.2.3.1 Chemistry and Biology of S-nitrosothiols
In order to understand the physiological properties of RSNO compounds, basic chemical 
aspects such as formation and decomposition must be discussed.
i) RSNO formation
RSNO formation in vitro generally occurs via reaction between protonated nitrite (HNO2) 
and thiols at the pH around 2 since the pKa of HNO2 is 3.37.
HONO + RSH ------------► RSNO + HzO
Since these are highly unlikely conditions to occur in the cell, another reaction that takes 
place is called transnitrosation.
RSNO + R’SH ------------► RSH + R’SNO
As shown in the above reaction, the RSNO compound is able to transfer its NO moiety to 
another thiol (RSH) molecule without releasing *NO. This mechanism is most likely the 
way by which various protein thiols become S-nitrosated.
ii) RSNO decomposition
Decomposition of RSNO may occur either by homolytic or by heterolytic cleavage as 
shown in the following reactions (Amelle and Stamler, 1995).
1. Homolytic cleavage
r \
R ^ —~ N = 0  ---------- * RS* + NO*




RS — N = 0  --------- -  RS+ + NO
A
RS — N = 0  -----------► RS + NO+
Homolytic cleavage occurs when the S-N bond is broken in such a way that one electron 
remains on sulfur and one on nitrogen generating RS* and *NO, respectively. During 
heterolytic cleavage, the S-N bond breaks and two electrons are either transferred to 
nitrogen resulting in NO' and RS+, or to sulfur thereby producing NO+ and RS' species. 
The presence of specific metal ions such as iron, mercury and copper also results in the 
generation of *NO from RSNO (Williams, 1996; Vanin et a l, 1997). Iron and copper 
decompose RSNO in a similar manner which involves reduction of the cupric ion (Cu2+) 
by thiolate to a cuprous ion (Cu+), followed by the reaction of Cu+ with RSNO via an 
intermediate formation [I] to generate *NO, RS* and Cu2+ which can then initiate the next 
reaction (Vanin et a l, 1997) (Figure 1.16, A). On the contrary, mercury is believed to 
form a complex with RSNO by coordination with the sulfur atom (Williams, 1996) 
subsequently producing HNO2 , as the product of RSNO decomposition (Figure 1.16, B). 
Finally, RSNOs can be decomposed via UV radiation resulting in a homolytic cleavage 
and radical formation (Figure 1.16, C) (Sexton et al., 1994).
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A B
Cu2+ + RS- -----*• Cu+ + RS* RSNO + Hg2+ <--------> [RS(Hg)NO]2+
Cu+ + RSNO — » [I]------ * Cu2+ + RS- + NO* [RS(Hg)NO]2+ + HzO->RSHg+ + H N 02 + H+
2 RS* -----* RSSR
C
hv
RSNO > RS* + *NO
RS* + RSNO — > RSSR + *NO
Figure 1.16: Decomposition of RSNO
1.2.3.2 Proteins and S-nitrosothiols
Since RSNOs are physiologically found throughout the cell, it is not surprising that many 
proteins and enzymes are involved in either the decomposition of RSNO or are possible 
targets for transnitrosation reaction.
RSNO consumption/degradation has been demonstrated in vitro by various enzymes such 
as thioredoxin/thioredoxin reductase (Nikitovic and Holmgren, 1996), xanthine/xanthine 
oxidase (Trujillo et al., 1998), y glutamyl transpeptidase (Lipton et al., 2001), Cu/Zn 
superoxide dismutase (Johnson et al., 2001; Romeo et al., 2003), glutathione dependent 
formaldehyde dehydrogenase (Jensen et al., 1998; Liu et al., 2001), and protein disulfide 
isomerase (Ramachandran et al., 2001).
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The mechanisms describing the formation of S-nitrosated proteins are currently under 
investigation, although there are a few groups that have proposed several possibilities. 
For example, Noble and Williams (2001) showed in vitro that nitrosated serum albumin 






Figure 1.17: Albumin mediated RSNO formation (Rafikova et al., 2002)
Rafikova and coworkers (Rafikova et a l, 2002) studied S-nitrosation of serum albumin 
and proposed the mechanism as shown in Figure 1.17. In the presence of *NO and O2 , 
formation of N2O3 , a potent nitrosating agent, may occur in the hydrophobic pockets of 
serum albumin which results in three possible outcomes. In the presence of small 
molecular weight thiols, such as GSH, direct transnitrosation may occur resulting in the 
formation of RSNO (Figure 1.17, a). A second possibility involves transfer of nitrosyl 
cation (NO+) and subsequent nitrosation of the surface exposed cysteine 34, which can 
then transnitrosate available RSH molecules (Figure 1.17, b). Similarly, the transfer of
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
31
N 0+ to the nearby tryptophan 214 yields the same result (Figure 1.17, c). Regardless of 
the pathway, the ability of proteins to consume N2O3 in their hydrophobic pockets may 
serve as the physiological source of #NO which consequently leads to formation of 
RSNOs or transnitrosation with other protein thiols.
There are numerous enzymes that upon S-nitrosation lose their activity such as alcohol 
dehydrogenase, aldehyde dehydrogenase, aldolase, calpain, cathepsin B, creatine kinase, 
cysteine protease, cytochrome P-450, glutathione peroxidase, glutathione reductase, 
glyceraldehyde-3-phosphate dehydrogenase, methionine synthase, protein kinase C, to 
name a few (Buga and Ignarro, 2000).
1.3 Role in disease
As described above, nitric oxide possesses a unique chemistry and biology, thus it is not 
surprising that it plays a major role in number of physiological conditions. Some of them 
will be discussed in the following section.
1.3.1 Diabetes
The general cause of diabetes is the inability of insulin to stimulate glucose uptake either 
by i) the absence or decreased production of insulin by P-cells in pancreas as in Type I 
diabetes or ii) inability o f insulin to stimulate the insulin signaling pathway as in Type II 
diabetes, leading to an increase in circulating sugar levels. Previous studies have shown 
that cytokine IL-1 modulates P-cell function and islet damage by inhibiting insulin 
secretion (Mandrup-Poulsen et al., 1985; Bendtzen et al., 1986). Initially, it was
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hypothesized that nitric oxide may be involved in mediating cytokine-induced inhibition 
of insulin secretion by (3-cells, since nitric oxide targets and either activates or inhibits 
iron-sulfur centers in proteins, such as cytokine IL-1 (Corbett and McDaniel, 1992). This 
hypothesis was confirmed with the use of NOS inhibitors to show prevention in cytokine- 
induced inhibition of insulin secretion (Corbett et al., 1991). Therefore, nitric oxide is 
involved in the inhibition of insulin secretion that eventually leads to P-cell death.
1.3.2 Cardiovascular disease
The use of nitric oxide donors in treatment of cardiovascular disease dates back in 19th 
century when William Murrell in 1879 reported that administration of nitroglycerin 
relieved attacks of angina pectoris (Murrell, 1879). It was not until 1980s when the 
endothelium-derived relaxing factor was discovered to be indeed nitric oxide (Reviewed 
in Ignarro, 2000). Nitric oxide mediates the vascular tone of the endothelium by 
providing vasorelaxation and a number of processes that lead to the development of 
cardiovascular disease such as inhibition of platelet aggregation (Stamler et al., 1989), 
leukocyte adhesion (Bath et al., 1991), endothelial generation of reactive oxygen species 
(Clancy et al., 1992) and proliferation of vascular smooth muscle (Garg and Hassid 
1989).
1.3.3 Apoptosis
Apoptosis, also known as a programmed cell death, is accompanied by a series of events 
such as cell shrinkage, chromatin condensation, cellular membrane blebbing and DNA 
degradation (Wylie et al., 1980; Roy et al., 1992). *NO mediates apoptosis in a dose-,
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time- and cell type-dependent process (Ponte and Huot, 1996). Ponte and Huot 
investigated the effect of nitric oxide on total intracellular thiol concentration and found 
that at the sublethal concentrations of *NO, glutathione levels were increased (Ponte and 
Huot, 1998). This observation was explained by the theory that, in response to the 
nitrosative stress induced by *NO, cells start producing stress proteins that help scavenge 
reactive oxygen species, as well as mobilize their antioxidant system consisting of 
increased levels of GSH, superoxide dismutase and catalaze. Therefore, the *NO plays a 
dual role in apoptosis; it either promotes it, or protects from it.
1.3.4 Cancer
The role of *NO in cancer is as variable as in apoptosis. Basal *NO levels are thought to 
promote tumor progression, while a high dose of »NO leads to tumor regression (Buga 
and Ignarro, 2000). One of the mechanisms of *NO mediated tumor progression involves 
regulation of the tumor-suppressor protein p53, which is either mutated or deleted in 
many human cancers. *NO may modify the p53 DNA-binding domain consisting of a 
tetrahedrally coordinated Zn atom bound to cysteine residues, by either binding to 
cysteine residues or coordinating with the Zn atom. Both of these interactions would 
result in a conformational change in p53, resulting in its inactivation and propagation of 
cancer (Calmels et al., 1998).
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CHAPTER 2
Characterization of S-Denitrosation Activity of Protein
Disulfide Isomerase
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2.1 Introduction
Although protein disulfide isomerase (PDI) was first isolated and identified in the 1960s 
(Goldberger et al., 1963) as a resident of the endoplasmic reticulum (ER) where it assists 
in folding of the newly synthesized proteins by performing its isomerase activity (Noiva 
and Lennarz, 1992), new roles for PDI are still being discovered. Not too long ago, PDI 
was found in the secreted form and associated with the surface of the cells via 
electrostatic interactions (Zai et a l, 1999 Terada et a l, 1995). The question which arises 
is what is PDI doing on the cell surface? One potential answer came from the study of 
Chen and coworkers (1995), who showed that PDI associated with the surface of the 
platelets plays a role in the integrin mediated platelet aggregation and adhesion as 
described in Chapter 1, Figure 1.7. The most studied functions of cell surface PDI 
involve either disulfide reduction, thiol oxidation or disulfide rearrangement (Chapter 1, 
Figure 1.6, 1.8). However, the study by Ramachandran and coworkers (Ramachandran, 
2001) showed that cell surface PDI was also able to denitrosate S-nitrosoglutathione 
(GSNO) and transport the nitric oxide (»NO) equivalents into the cytosol. Another study 
performed by Root and coworkers (2004, a part of Chapter 3) showed that platelet 
surface PDI was also able to denitrosate GSNO and by doing so, platelet aggregation was 
abolished. Therefore, the role of PDI on the surface of the cells may have a greater role 
than its usual isomerization activity.
S-nitrosothiols (RSNOs) are known nitric oxide donors (Feelisch, 1998). 
Physiologically, RSNO may be small molecular weight thiols such as S- 
nitrosoglutathione, S-nitrosocysteine and S-nitrosohomocysteine, as well as high 
molecular weight S-nitrosated proteins such as serum albumin. *NO has a very short half
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
36
life (2-5 seconds) (Balbatun et al., 2003) and by forming an RSNO, its half life is 
prolonged up to several hours (Whiteside et al., 2002). The RSNO bound-NO could be 
transported throughout the cellular environment such as in the case o f S-nitrosated serum 
albumin (Rafikova et al., 2000) and S-nitrosated hemoglobin (Jourd’heuil et al., 2000).
The current study was initiated since the PDI-mediated denitrosation acitivity of RSNOs 
has not been well characterized. The RSNO used here was S-nitrosoglutathione, as it is 
the most physiological small RSNO found in the body (Clancy et al., 1994). The RSNO 
decomposition was monitored using two methods. In the first method, the decrease in 
absorbance of the S-NO bond at 334 nm was used to detect its cleavage due to PDI 
(Williams, 1996), while the second method made use of an amperometric device for 
measuring soluble nitric oxide (Zhang and Broderick, 2000). For detection of thiyl and 
dithiyl radicals, we used a conjugate of acridine and TEMPO (2,2,6,6 - 
tetramethylpiperidine-l-oxyl), which is a nonfluorescent probe until it reacts with thiyl 
radicals resulting in acridine-piperidine which is highly fluorescent (Borisenko et al., 
2004). We also used a non-specific nitric oxide probe, diaminonaphthalene for measuring 
the presence of nitric oxide species. We addressed the fate of nitric oxide after it has 
been released and showed that PDI was able to store nitric oxide in the form of N2O3 in 
its hydrophobic pockets. This stored nitric oxide was then able to react with exogenous 
thiols and transfer its »NO equivalents.
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2.2 Materials and Equipment
2.2.1 Materials
Acetone; Sigma-Aldrich Canada Ltd., Oakville, Ontario
4-(9-Acridinecarbonyl)-amino)-2,2,6,6-tetramethylpiperidine-l-oxyl (Ac-Tempo);
Molecular Probes, Eugene, OR 
Ammonium persulfate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ammonium sulfamate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Biorad Bradford Reagent; Bio-Rad Laboratories Ltd., Mississauga, Ontario
Bovine Serum Albumin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Copper (II) sulfate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
2 ,3 -diaminonaphthalene (DAN); Sigma-Aldrich Canada Ltd., Oakville, Ontario
Diethylamine NONOate (DEANO); Sigma-Aldrich Canada Ltd., Oakville, Ontario
Dimethyl formamide (DMF); Sigma-Aldrich Canada Ltd., Oakville, Ontario
5, 5’-dithiobis(2-nitrobenzoic) acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Dithiothreitol (DTT); Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ethylene diamine tetraacetic acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Hemoglobin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Monoclonal anti-PDI antibody RL90;Abcam USA, Cambridge, MA 
Imidazole; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Neocuprine; Sigma-Aldrich Canada Ltd., Oakville, Ontario
N-ethylmaleimide (NEM) Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ni-Cam™ Resin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
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Oxidized glutathione; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Potassium ferricyanide; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Potassium phosphate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Reduced glutathione; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sephadex G-25; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium chloride; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium dithionate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium hydroxide; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium nitrite; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium phosphate monobasic: Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium phosphate dibasic; Sigma-Aldrich Canada Ltd., Oakville, Ontario
TEMED; Bio-Rad Laboratories Ltd., Mississauga, Ontario
2.2.2 Equipment
Agilent 8453 UV-VIS spectrophotometer;
(Agilent Technologies Canada Inc, Mississauga, Ontario) 
Beckman J2-HS Centrifuge;
(Beckman Coulter Canada Inc., Mississauga, Ontario) 
BioRad Fraction Collector Model 2110;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario) 
ISO-NO Mark II with WPIMKII Nitric Oxide electrode;
(World Precision Instruments Inc., Sarasota, Florida) 
Jouan CR3i Centrifuge;
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(Jouan Inc, Winchester, Virginia)
Labconco FreeZone 4.5 Liter Benchtop Freeze Dry Systems;
(Labconco Corporation, Kansas City, Missouri) 
Mettler AJ100 Balance;
(Mettler Toledo Canada, Mississauga, Ontario) 
Microtiter 96-well Solid Plate;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Mini-Protein II Gel Electrophoresis System;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario) 
Orion Model 420A pH Meter;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Stir Plate 360 Series;
(VWR International, Mississauga, Ontario)
Varian Eclipse Fluorescence Spectrophotometer;
(Varian Canada, Mississauga, Ontario)
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2.3 Experimental Methods
2.3.1 Purification of Protein Disulfide Isomerase
The expression vector pET-28b was prepared by Seslija (Seslija MSc Thesis, 2005) from 
Dr. Lana Lee’s lab and generously donated to our lab. The vector contained the entire 
human PDI sequence with the N-terminal His6 tag (Pihlajaniemi et al., 1987). The pET- 
28b vector was transformed to Escherichia coli strain BL21 (DE3), and protein 
expression was induced with 1 mM isopropylthiogalactoside. Following cell lysis, 
purification of recombinant PDI from the soluble fraction of cell lysate was performed 
using a high capacity nickel affinity matrix, Ni-CAM™ HC Resin. After several washes 
with 30 mM imidazole to remove any non specific binding, PDI was eluted using 250 
mM imidazole prepared in 50 mM Tris-HCL, pH 8.0 and collected in 2.0 mL fractions 
using a Bio-Rad fraction collector. The fractions containing PDI were pooled and 
dialyzed against 100 mM potassium phosphate buffer, pH 7 in order to remove 
imidazole. Bradford assay was used to quantify protein using bovine serum albumin as a 
standard (Bradford, 1976). The purity of protein was determined by SDS-PAGE gel 
electrophoresis and Western blotting.
2.3.2 PDI Assay Buffer
Unless otherwise specified, all experiments were performed in the PDI assay buffer 
containing 100 mM potassium phosphate, pH 7.0, and 2 mM EDTA.
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2.3.3 Synthesis of S-Nitrosoglutathione
The free thiol concentration in the GSH was determined by DTNB assay (Jiang et al., 
1999). A stoichiometric amount of acidified NaNC>2 (pH 2) to the free thiol 
concentration of GSH, was reacted with GSH for 30 minutes at 4°C, followed by the pH 
adjustment to 7.4 using NaOH (2 M). GSNO was recrystallized by the slow addition of 
ice-cold acetone and resuspended in the appropriate buffer.
2.3.4 Preparation of Oxyhemoglobin and Methemoglobin
Oxyhemoglobin and methemoglobin were prepared as described by Nikitovic and 
Holgren (1996). Briefly, oxyhemoglobin was prepared by the reduction of human 
hemoglobin with dithionate in 100 mM potassium phosphate, pH 7.4, followed by the 
chromatographic separation using Sephadex G-25. Methemoglobin was prepared by 
oxidizing human hemoglobin with 5% molar excess of potassium ferricyanide in 100 mM 
potassium phosphate, pH 7.0, followed by chromatographic separation of unreacted 
species using a Sephadex G-25 column equilibrated with the same buffer. 
Oxyhemoglobin and methemoglobin were prepared fresh prior to each experiment and 
conformation of their characteristic heme state was obtained by monitoring specific peak 
appearance at 542 nm and 580 nm for oxyhemoglobin and 630 nm for methemoglobin by 
UV-vis spectrophotometry.
2.3.5 Hemoglobin Assay
The hemoglobin assay was used to determine the final product of GSNO cleavage by PDI 
(Amelle and Stamler, 1995). Detection of *NO can be achieved though the oxidation of
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
42
oxyhemoglobin to methemoglobin, which can be monitored as a decrease in absorbance 
at 542 and 580 nm and an increase at 630 nm (Bazylinski and Hollocher, 1985; Stone and 
Marietta, 1994). The reaction mixture contained 30 pM oxyhemoglobin, 1.2 mM GSH, 
100 pM GSNO (blank), and 2 pM PDI (sample), in 100 mM potassium phosphate buffer, 
pH 7.4, containing 1 mM EDTA. The possibility of NO' generation was monitored via 
methemoglobin reduction to oxyhemoglobin which would result in an increase in 
absorbance peak at 542 nm and 580 nm and a concomitant decrease at 630 nm. The 
assay solution contained 30 pM methemoglobin, 1.2 mM GSH, 100 pM GSNO (blank) 
and 2 pM PDI (sample), in 100 mM potassium phosphate buffer, pH 7.0, including 1 mM 
EDTA. All spectra were recorded from 500-700 nm at specific time intervals. The 
extinction coefficient for oxyhemoglobin at pH 7.0 is 13900 M^cm ' 1 and 14000 M"‘cm ' 1 
at 545 and 580 nm (Bazylinski and Hollocher, 1985), respectively, whereas the GSNO 
extinction coefficient of 15 M 'Icm' 1 at 545 nm (Hart, 1985) and is therefore considered 
insignificant.
2.3.6 Direct Monitoring of PDI Denitrosation Activity with UV-visible 
Spectroscopy
The kinetcs of PDI-mediated denitrosation activity o f GSNO was monitored as the 
decrease in absorption at 340 nm as a function of time. The reaction was performed in a 
PDI assay buffer containing various [GSNO] (10-500 pM) as a substrate, 3 pM PDI and 
GSH (1.2 mM) to study the kinetic parameters. PDI denitrosation activity was also 
monitored using a nitric oxide meter (described below) in order to directly detect NO
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generation due to GSNO cleavage. All measurements were performed at the room 
temperature.
2.3.7 Detection of PDI Radicals with Ac-Tempo
Previous studies reported that Ac-Tempo, a paramagnetic nonfluorescent conjugate of 
2 ,2 ,6 ,6 -tetramethylpiperidine-l-oxyl and acridine, interacts with glutathionyl radicals 
resulting in an increase in fluorescence of acridine-piperidine moiety (Borisenko et al., 
2004). The Ac-Tempo concentration was first determined by measuring the absorbance 
at 359 nm (s=10.4 mM'1cm"1), and fluorescence measurements were performed with 
excitation and emission wavelengths of 360 nm and 440 nm, respectively. PDI radical 
formation was detected by mixing stoichiometric amounts of PDI and GSNO (2 pM) 
with Ac-Tempo (10 pM), followed by the time-dependent measurement of fluorescence 
at 440 nm (Xex= 360 nm). The control reaction was performed using DTT and GSH 
instead of PDI, to determine whether any compound with vicinal thiols could also 
generate GSv As another control, BSA was used in the same amount as PDI to see if 
there is a possibility of another protein interacting with the Ac-TEMPO probe. The 
standard plot of thiyl radical formation was constructed using photolysis (355 nm) 
(Sexton et al., 1994) and employing various concentrations of GSNO (1-20 pM) in the 
presence of Ac-Tempo followed by florescence measurements. This standard plot was 
used for quantification of thiyl/dithiyl radicals.
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2.3.8 Generation of a Standard Curve with DAN
A standard curve was generated by incubating varying concentrations of GSNO (200 nM 
to 25 pM) in the presence of DAN (200 pM) and HgCl2 (100 pM) for 10 minutes in PBS 
(100 mM phosphate, pH, 7.4) at room temperature. The fluorescence readings were 
recorded at 415 nm with an excitation at 375 nm. The amount of NOx generated 
experimentally was estimated using this standard curve.
2.3.9 Demonstration of the Ability of BSA and PDI to Store NO-equivalents
In order to demonstrate that BSA and PDI are able to store NO-equivalents, 25 pM 
GSNO was incubated with 100 pM HgCl2 for 10 minutes in the presence of 1, 2, and 4 
pM BSA or PDI, followed by the addition of ammonium sulfamate (0.1 %) to remove the 
excess of HNO2 . The increase in fluorescence using DAN (200 pM) was monitored as a 
function of time at 415 nm (A,ex 375 nm), as an indicative of the presence of NOx. All 
experiments were performed in 100 mM PBS buffer, pH 7.4, at the room temperature.
2.3.10 Preparation of PDI-reduced and S-nitrosated PDI (PDI-SNO)
Reduced PDI was prepared by treatment with 10-fold molar excess of DTT for 30 
minutes at room temperature, followed by the overnight dialysis (MW cutoff 5 kDa) in 
20 mM phosphate buffer, pH 6.3 at 4°C. The concentration of free thiols was quantified 
by the DTNB assay. S-nitrosated PDI (PDI-NO) was prepared by incubating reduced 
PDI with 5 -fold molar excess of DEA-NO for 30 minutes at the room temperature. The 
degree of nitrosation of PDI was assessed using an NO meter with HgCl2 as the NO 
releasing agent (Borisenko et al., 2004) as described below.
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2.3.11 Nitric Oxide Determination Using an NO Meter
Soluble nitric oxide was measured using ISO-NO Mark II Nitric Oxide meter equipped 
with WPIMKII NO electrode. A standard curve for NO was generated by adding GSNO 
(10-100 pM) to 100 mM phosphate buffer, pH 7.0, containing 100 pM HgC^. In order 
to test for S-nitrosated PDI, PDI-NO (1 pM) was placed in the vial containing 100 mM 
phosphate buffer, pH 7.4, and the electrode was blanked using this mixture. At 20 sec, 
100 pM HgCh was added, and the *NO generation was monitored until *NO was no 
longer detected. In a parallel experiment, 2 pM reduced PDI was added to PDI-NO to 
verify whether PDI alone could act upon PDI-NO. In a control experiment, BSA (2 pM) 
was used instead of PDI as another possible protein to contribute to PDI-SNO 
denitrosation.
To test the involvement of the active site thiols, NEM-blocked PDI was incubated with 
DEA-NO for 30 minutes at the room temperature, to generate *NO saturated PDI. 3 pM 
of this NO-saturated PDI was placed in the vial containing 100 mM phosphate buffer, pH 
7.4, and the NO signal was measured as a base line for the first 40 seconds. At 40 
seconds, 100 pM HgCl2 was added to remove any S-NO present in the sample. After 
obtaining a stable signal at 130 seconds, 500 pM GSH was added to potentially scavenge 
N2O3 postulated to be present in the hydrophobic domains of PDI. The control was 
obtained using NEM-blocked PDI without exposure to DEA-NO. The actual »NO 
concentration was estimated from the standard curve.
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2.3.12 Quantification of Thiols in PDI
In order to quantify the stability of PDI thiols, 10 pM PDI was incubated with 10 mM 
DTT for 1 hour at the room temperature, followed by the chromatographic separation of 
DTT via Sephadex G-25. 1.2 pM PDI was then incubated with DTNB for 30 minutes at 
different time intervals and the absorbance was monitored at 412 nm in 100 mM Tris- 
HC1 buffer, pH 8  (s= 13900 M"1cm' 1 at 412 nm).
2.3.13 Monitoring PDI-SNO Formation by UV-visible Spectroscopy
Freshly reduced PDI (10 pM) was treated with DEA-NO for 30 minutes, followed by 
separation through a Sephadex G-25 column. The absorption spectra of PDI-SNO were 
monitored between 300 nm-450 nm. The *NO dissociation from PDI-SNO was initiated 
by the addition of HgCl2 , and the quantification of S-nitrosation was obtained by 
monitoring a decrease in absorbance at 340 nm using the molar extinction coefficient of 
980 M '1cm'1.
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2.4 Results
The experiments involving spectrophotometric analysis of PDI-mediated GSNO 
denitrosation and DAN assay were performed by my colleague, Dr. Arun Raturi.
2.4.1 Kinetics of PDI mediated GSNO denitrosation
The initial rates of PDI-mediated GSNO denitrosation were obtained using two different 
methods. In the first method, the initial rates of denitrosation were monitored 
spectrophotometrically at 340 nm to detect the loss of the S-NO bond absorbance in the 
presence of PDI (3 pM), GSH (1.3 pM) and a range of [GSNO] (0-500 pM). Initial rates 
as a function of [GSNO] were accommodated with the Michaelis-Menten equation and 
the apparent Km for GSNO was estimated to be 65 ± 5 pM (Figure 2.1 A). In the second 
method, PDI (2 pM) denitrosation activity in the presence of GSNO (10-140 pM) was 
monitored by an NO electrode. The apparent Km was estimated to be 40 ± 10 pM 
(Figure 2.1 B). The slightly higher Km observed spectrophotometrically is probably due 
to the uncertainty in the initial rates at low GSNO concentration owing to the low 
extinction coefficient of the S-NO bond at 340 nm (e=980 M '1cm'1).
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Figure 2.1 : PDI denitrosation kinetic summary.
A. Samples containing PDI (3juM) were mixed with 1.2 mM GSH, and denitrosation 
was monitored at 343 nm as a function of time. The rates were corrected by subtracting 
the blank rates (without PDI) and plotted against increasing GSNO concentrations. The 
solid line represents the best fit of the calculated data based on the experimentally 
determined kinetic parameters using the Michaelis-Menten equation.






B. Sample containing PDI (3//M) was mixed with 1.2 mM GSH and an NO 
electrode was placed in the mixture. PDI denitrosation activity was initiated by the 
addition of increasing GSNO concentrations. *NO generated by PDI was obtained after 
correcting for release by 1.2 mM GSH, using an *NO standard curve.
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The end product of PDI-mediated GSNO denitrosation could be either NO’ or NO'. In 
order to identify the actual product of PDI denitrosation activity, a hemoglobin assay was 
performed (Amelle and Stamler, 1995). Oxyhemoglobin was incubated with GSNO, 
GSH and without (blank) or with PDI (sample), and a time dependent decrease at 542 nm 
and 580 nm and in increase at 630 nm indicated the formation of methemoglobin, 
suggesting that the major product of PDI-mediated GSNO denitrosation was indeed NO' 
(Figure 2.2 A). In order to test for the second possibility of NO' generation, a 
methemoglobin assay was performed using the same experimental set up as for the 
oxyhemoglobin assay. If NO' were produced, it would reduce methemoglobin that could 
be monitored by an increase in absorbance at 540 and 580 nm accompanied by a decrease 
at 630 nm. As Figure 2.2 B shows, methemoglobin spectra in the presence of PDI and 
GSNO was stable over 20 minutes, suggesting that if  any NO' was being produced, it was 
below the detection limit of this assay.
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Figure 2.2: Monitoring NO'/NO' release by hemoglobin assay.
A. Oxyhemoglobin assay contained 30 /zM oxyhemoglobin, 1.2 mM GSH, 100 juM 
GSNO and 2 /JM PDI in 100 mM potassium phosphate, 1.0 mM EDTA, pH 7.4. A 
decrease at 542 and 580 nm, and consequential increase at 630 nm was an indicative of 
NO" production. The reaction was over in approximately 12 minutes.
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B. Methemoglobin assay contained 30 /lM. methemoglobin, 1.2 mM GSH, 100 /uM 
GSNO and 2 juM PDI in 100 mM potassium phosphate, 1 mM EDTA, pH 7.4. There was 
no change in spectrum observed over 20 minutes o f incubation indicating the lack of NO' 
production during GSNO denitrosation by PDI.
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2.4.2 PDI Thiyl/dithiyl Radical Formation as a Result of GSNO Denitrosation
A previous computational study by Houk and coworkers (Houk et al., 2003) suggested a 
novel mechanism for transnitrosation reaction involving the formation of a nitroxyl 
disulfide intermediate, given that the interacting thiols are in a close proximity to each 
other as in PDI active site. Therefore, if PDI active site thiols were part of such a 
mechanism, then beside *NO generation, there should also be a consequent thiyl/dithiyl 
radical formation. For this purpose, a thiyl radical probe, Ac-Tempo, was used. Previous 
studies have shown that Ac-Tempo, upon interacting with thiyl radicals gives off a 
fluorescent signal. Therefore, we set to determine whether PDI could form a thiyl radical 
in its active site as a result of GSNO denitrosation. In a control trial, GSNO was added to 
the cuvette containing Ac-Tempo alone and the lack of fluorescence suggested that there 
is no spontaneous interaction between GSNO and Ac-Tempo (Figure 2.3 A, triangles). 
However, upon addition of equimolar (2 pM) PDI and GSNO to Ac-Tempo (10 pM), a 
continuous, time-dependent increase in fluorescence was observed (Figure 2.3 A, 
squares). As a control, the experiment was performed in the presence of BSA instead of 
PDI and no fluorescent signal was observed upon addition of GSNO (Figure 2.3 B 
asterisk). Also, to eliminate the possibility that the signal comes from the second product 
of GSNO denitrosation (GS), the same experiment was performed in the presence of 
GSH and PDI, and no detectable fluorescent signal was observed (Figure 2.3 B, filled 
circles). By converting the fluorescent signal obtained by Ac-Tempo experiments to the 
actual thiyl radical formation (Figure 2.4, squares) and the generation of *NO from 
oxyhemoglobin experiments (Figure 2.4 diamonds), we were able to quantify that 0.8 ±
1.2 mol of NO was produced per 3 ± 0.43 mol of thiyl/dithiyl radical formed.
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Figure 2.3: Thiyl/dithiyl radical generation due to PDI mediated GSNO 
denitrosation.
A. Ac-Tempo (10 pM) was placed in a cuvette containing buffer only (triangles) or PDI 
(2 pM; squares). After a stable signal was obtained by monitoring fluorescence at 440 
nm (excitation 360 nm), GSNO (2 pM) was added and the generation of thiyl/dithiyl 
radical was observed.
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B. Ac-Tempo (10 pM) was placed in a cuvette containing BSA (2 pM; asterisk) or PDI 
(2 pM; filled circles). After a stable signal was obtained by monitoring fluorescence at 
440 nm (excitation 360 nm), GSNO (2 pM) was added to the sample containing BSA and 
GSH was added to the sample containing PDI. The generation of thiyl/dithiyl radical was 
monitored over 30 minutes.
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Figure 2.4: Quantification of *NO and thiyl/dithiyl radical generation during PDI- 
medaited GSNO denitrosation.
Ac-Tempo (10 pM) was mixed with 2 pM PDI and 2 pM GSNO, and the fluorescent 
signal was measured over time {squares). In parallel experiments, 40 pM oxyhemoglobin 
(HbOi) was mixed with 2 pM PDI and 2 pM GSNO, and the decrease at 542 nm 
(indicative of NO-induced methemoglobin formation) was monitored over time 
(diamonds). The rates of NO formation and thiyl/dithiyl radical formation were nearly 
superimposable. The yields were 0.8 ± 0.12 mol NO produced/ 3.0 ±0.43 mol 
thiyl/dithiyl radical (n =3). Inset, standard plot of Ac-Tempo fluorescence (in relative 
fluorescence units (RFU)) as a function of [GS*] generated by flash photolysis (355 nm) 
of varying concentrations of GSNO.
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2.4.3 PDI and BSA Act as a NO Sink
Previous studies (Rafikova et al., 2002) have shown that proteins containing hydrophobic 
domains, such as serum albumin, are able to accumulate *NO and O2 in the form of the 
potent nitrosating agent N2O3 . Here, we used the DAN assay to test if PDI could also 
behave in the same manner. DAN works on the basis of N-nitrosation of the amino 
group by »NO as well as other reactive nitrogen species such as NO2" and N2O3 
(Kleinhenz et al., 2003; Wink et al., 1999). The second amino group of DAN then reacts 
with the nitrosated intermediate, resulting in the highly fluorescent naphthotriazole 
derivative. In this experiment, the NO was generated by incubating GSNO (50 pM) with 
HgCl2 (Williams, 1996) in the presence of 1, 2 and 4 pM of BSA (Figure 2.5 A) or PDI 
(Figure 2.5 B). As seen in Figure 2.5 A and B, the amount of naphthotriazole decreased 
with increasing concentration of each protein, suggesting that there was a decrease in 
soluble NOx available to react with DAN.
Nudler and coworkers (Rafikova et al., 2002) have shown that the accumulated N2 O3 
inside the hydrophobic pockets of BSA could potentially nitrosate protein thiols. In this 
study, the most likely target for S-nitrosation would be the active site thiols of PDI. 
Based on this proposal, the following experiments were performed.














2 3 4 510
Time (min)
Figure 2.5: Monitoring denitrosation rate using the DAN assay
A. Denitrosation of GSNO with HgCl2 in the presence of BSA: 25 //M of GSNO 
was incubated with 100 juM copper sulphate for 10 min in the presence of varying 
concentration of BSA followed by the addition of ammonium sulfamate (0.1%) to 
remove excess of H N 02. DAN (200 //M) was added and the denitrosation rate was 
monitored as a function of time. The experiment was performed in 0.1 mM PBS buffer, 
pH 7.4 at room temperature.
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B. Denitrosation of GSNO with HgC^ in the presence of PDI: 25 fM  of GSNO was 
incubated with 100 /A l copper sulphate for 5 min in the presence of varying 
concentration of PDI followed by the addition of 200 //M DAN. Ammonium sulfamate 
(0.1%) was added to remove excess HNO2 . The experiment was performed in 0.1 mM 
PBS buffer, pH 7.4 at room temperature.
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2.4.4 PDI Can Release NO from PDI-SNO
The ability o f PDI to be nitrosated was tested by the DTNB assay. Reduced PDI was 
prepared by incubating native PDI with 10-fold molar excess DTT, followed by 
chromatographic separation on a Sephadex G-25 column. Freshly reduced PDI was 
incubated with DTNB and the total thiol concentration was found to be ~4 ± 0.25 mol per 
mole of PDI (Figure 2.6). However, freshly reduced PDI incubated with an excess of 
DEA-NO, and then subjected to the DTNB assay, showed a significant decrease in thiol 
concentration (0.25 ± 0.05 mol per mole of PDI) (Figure 2.6).
In order to further validate that PDI is being S-nitrosated at its cysteine residues, the 
absorption spectrum of PDI-SNO formed by incubating freshly reduced PDI with DEA- 
NO was obtained. As seen in Figure 2.7, PDI-SNO spectrum gave a peak at 340 nm, an 
indicative of S-NO bond formation.
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Figure 2.6: Thiol quantification by DTNB of PDI and PDI-SNO
Monitoring total thiols of PDI and PDI-SNO was performed by incubating PDI (10 pM) 
with 10 mM DTT for 1 hour at the room temperature, followed by chromatographic 
separation using a Sephadex G-25 column. 2 pM PDI was then incubated with excess 
DTBN in 100 mM Tris-HCl buffer, pH 8.0 and the absorbance at 412 nm was obtained. 
PDI-SNO was prepared by incubating freshly reduced PDI with excess DEA-NO 
followed by the removal of unreacted species using Sephadex G-25. Immediately after 
obtaining PDI-SNO, the sample was incubated with DTNB and the absorbance at 412 nm 
was measured.
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Figure 2.7: Validation of S-nitrosated PDI
Freshly reduced PDI (10 pM) was incubated with excess DEA-NO for 30 minutes at 
room temperature, followed by the chromatographic separation using Sephadex G-25 
column and PDI assay buffer. The absorption spectra from freshly reduced PDI and PDI- 
SNO in the range from 300-400 nm were obtained and the difference spectrum was 
obtained and plotted as shown above.
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
63
Next, we used the NO-meter approach to detect the release of *NO from PDI-SNO. In 
these experiments, an »NO electrode was placed in the buffer containing NO-saturated 
PDI (1.0 pM) and the "NO signal was monitored for 20 seconds to ensure there is no 
spontaneous *NO generation (Figure 2.8 A and B). At that time, HgCl2 (100 pM) was 
added and the increase in signal due to the release of *NO from PDI-SNO was monitored 
and corresponded to 4 ± 0.5 pM of »NO/pM of PDI (Figure 2.8 A). In a similar 
experiment, freshly reduced PDI (2 pM) was used instead of HgCl2 and this also resulted 
in the increase in signal corresponding to 4 ± 0.5 pM »NO/pM of PDI (Figure 2.8 B). 
Therefore, the »NO released form PDI-SNO was determined to be -4.5 pM/ pM of PDI, 
under these experimental conditions.










Figure 2.8: PDI-SNO denitrosation with Hg and PDI
A. PDI-SNO (1 pM) was placed in the vial and the NO meter was blanked using this 
solution. After a stable signal was obtained at about 20 seconds, 100 pM HgCl2 was 
added and the *NO generation was monitored until saturation was obtained.












B. PDI-SNO and PDI reduced was prepared as described in the “Experimental section”. 
A solution containing PDI-SNO was placed in the vial and the NO signal was monitored 
for 20 seconds to establish the baseline. At that time, reduced PDI was added to the 
sample and the *NO generation was monitored until saturation.
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Lastly, we wanted to explore the possibility of PDI storage of NO in the form of N2O3 in 
its hydrophobic pockets. For this purpose, freshly reduced PDI was incubated with 
NEM, in order to block free thiols, followed by the incubation with DEA-NO. This 
method ensured that there is no PDI-SNO formation.
When HgCL (100 pM) was added to the NEM-blocked NO-saturated PDI, no change in 
signal was observed. However, upon addition of GSH, a slow increase in signal was 
observed and the concentration of NO generated was found to be -10 ± 1 pM/ pM of PDI 
(Figure 2.9, dashed line). When the experiment was performed in the reverse order of 
addition of GSH and HgCL, the same trend was obtained. These results were interpreted 
in the following way: the generation of NO observed was likely due to the GSNO 
formation in the presence of GSH, which was then released by the addition of HgCl2 . 
These experiments suggested that PDI is able to store NO in the form of N2O3 under our 
experimental set up.











Figure 2.9: *NO storage by PDI
The ability of PDI to store *NO was tested by using NEM-blocked PDI (3 pM) saturated 
with *NO, as described under “Experimental methods”. After a stable signal was 
obtained, at 50 seconds, 100 pM HgCl2 (thick line) or 500 pM GSH (dashed line) was 
added and no signal change was observed. Addition of either 500 pM GSH (thick line) 
or 100 pM HgCl2 (dashed line) at 120 seconds resulted in a steady increase in current 
until saturation was obtained. Inset, control experiment obtained by the addition of BSA 
instead of reduced PDI to PDI-SNO, followed by the addition of HgCl2.
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2.5 Discussion
S-denitrosation activity of PDI was shown in several different studies (Zai et al., 1999; 
Ramachandran et al., 2001) but the actual mechanism is still unknown. In this study, we 
set to establish the kinetic parameters for PDI-mediated GSNO denitrosation using 
recombinant human PDI. The PDI-dependent denitrosation activity as a function of 
varying GSNO concentrations was studied using two different methods. The first one 
employed a spectrophotometric method taking advantage of absorbance of S-NO bond at 
340 nm, and the second one used a NO-meter to directly monitor *NO generation as a 
result of GSNO decomposition due to PDI activity. The Km using the spectrophotometric 
method was estimated to be 65 ± 5 pM (Figure 2.1 A), while the NO-meter experiments 
gave a value of 40 ± 10 pM (Figure 2.1 B).
Next we wanted to find out what was the end product of PDI-mediated GSNO 
denitrosation. For this purpose, the hemoglobin assay was employed and the results 
obtained showed that it is *NO and not NO' being formed during the GSNO denitrosation 
by PDI (Figure 2.2 A and B). This finding was in agreement with the previous study by 
Nikitovic and Holmgren that showed the same product as a result of reaction of GSNO 
and thioredoxin (Nikitovic and Holmgren, 1996). In the light of these results, a PDI 
denitrosation mechanism is proposed in Scheme 2.1. This mechanism involves an initial 
transnitrosation reaction of one of the cysteines in the PDI active site consisting of the 
CXXC sequence, with the RSNO substrate (Scheme 1 ,1 and II). Next step involves the 
attack on nitrogen of S-N=0 with the second active site cysteine resulting a nitroxyl 
disulfide intermediate (Scheme 1. III).
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Scheme 2.1. PDI denitrosation mechanism.
One of the vicinal thiols of PDI active site subunit a, undergoes transnitrosation reaction 
(I) in the presence of RSNO, followed by the attack of the second cysteine (II) at N of the 
S-N=0 resulting in formation of a nitroxyl disulfide intermediate (III), which could be 
stabilized by the nearby imidazole (Imht) of His589. One-electron reduction by the 
second active site of PDI (subunit a ’) leads to a formation of an unstable radical 
intermediate and dithiyl radical in subunit a’(IV). The final product after one enzymatic 
turnover is an oxidized protein active site of subunit a and »NO (V  and VI) (Nikitovic and 
Holmgren, 1996).
This formation is most likely due to the translocation of the electrons from the N=0 
double bond to N-O, which could then be stabilized by the positively charged side chain
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in the vicinity of the active site, such as Hisi6o in the a-domain or His 589 in the a’ 
domain (GenBank™ accession number AK027647). The next step involves a one 
electron oxidation leading to the formation of nitroxyl disulfide radical (Scheme 1, IV), 
which undergoes rearrangement to form oxidized S-S PDI active site plus *NO (Scheme 
1 , V and VI). The mechanism proposed is based on the recent study by Houk and 
coworkers (Houk et al., 2003) which showed by using a computational approach that the 
formation of such nitroxyl disulfide intermediate was possible. For this mechanism to 
work there is the requirement for an electron acceptor which could be either the second 
active site, based on the recent crystal structure of yeast PDI (Tian et al., 2006) the 
oxidized active site thiols of PDI dimer in the antiparallel arrangement (Solovyov and 
Gilbert, 2004). This hypothesis is also supported by the fact that PDI active site is the 
most oxidative (-180 mV) (Wilkinson and Gilbert, 2004) of all other members of 
thioredoxin-like family of proteins. In support of this, it has been reported that the 
oxidized active site thiols of DsbD, which is a prokaryotic PDI-like protein, can serve as 
the electron transporter via succession of disulfide exchange reactions (Rietsch et al., 
1997; Collet et al., 2002).
Additional evidence supporting this mechanism was obtained with the experiments using 
Ac-Tempo thiyl/dithiyl radical probe. By mixing equimolar concentrations of PDI and 
GSNO, thyil/dithyl radicals were generated (Figure 2.3 A) while GSNO alone was 
unsuccessful in reacting with the probe. In order to ensure that the radical formation 
observed was purely due to the PDI denitrosation activity, the experiments were 
performed using BSA and no detectable radical formation was observed (Figure 2.3 B).
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To further support our mechanism, the rate of thiyl/dithiyl radical formation was 
compared with »NO generation from oxyhemoglobin studies. The estimated 
stoichiometries of two independent experiments indicate that there are 3 moles of 
thiyl/dithiyl radical formed per 1 mole of NO produced (Figure 2.4). This experimental 
evidence is well accommodated by the proposed mechanism in Scheme 1, which suggests 
that the two active site S’ plus the S-S’ plus NO’ (Scheme 1, IV and V) are formed in a 
concerted manner rather than sequential.
Next, we wanted to find out what is the fate of *NO once released by PDI from GSNO. 
Previous studies (Rafikova et al., 2002) suggested that serum albumin was able to store 
NO in the form of N2 O3 in its hydrophobic pockets and potentially auto S-nitrosate its 
own cysteine resides. Our findings suggest that PDI behaved in the same manner, since 
the experiments using DAN and NO generated by GSNO and HgCh demonstrated a 
decrease in NO availability in the presence of increasing protein (BSA or PDI) 
concentrations (Figure 2.5 A and B).
In order to show that PDI thiols were able to undergo S-nitrosation in the presence of NO 
donor, the thiols of freshly reduced PDI or freshly reduced PDI exposed to DEA-NO was 
monitored with DTNB assay. As shown in Figure 2.6, freshly prepared PDI contained ~4 
moles of thiol per mole of PDI, while PDI exposed to DEA-NO essentially did not have 
any thiols available to react with DTNB. To ensure that this was due to S-nitrosation 
rather than oxidation of thiols, the absorption spectrum of S-nitrosated PDI was obtained. 
As seen in Figure 2.7, PDI-SNO showed a characteristic S-NO peak at 340 nm,
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supporting our hypothesis. Further, the NO-meter was used as an unambiguous method 
to detect NO released from PDI-SNO. When the sample containing PDI-SNO was 
exposed to either HgC^ (Figure 2.8 A) or freshly reduced PDI (Figure 2.7 B), 4 pM of 
•NO were rapidly released per pM of PDI. In order to support the proposal that PDI 
could act as a sink for N2O3, PDI was treated with NEM to ensure unavailability of active 
site thiols to undergo S-nitrosation, followed by the exposure to DEA-NO, to saturate 
PDI with N2 O3 . Upon addition of GSH followed by the addition of HgCl2 , this NEM- 
blocked NO-saturated PDI was able to generate -10 pM of NO per pM of PDI (Figure 
2.9). It is interesting to note that while the addition of HgCh followed by the addition of 
GSH resulted in the slower rate of *NO generation (Figure 2.9, dashed line), the reversed 
order caused a rapid liberation of *NO (Figure 2.9, solid line). This was probably due to 
the fact that when GSH was introduced first, it already started forming and accumulating 
GSNO, which was then readily available for cleavage by HgCU
In summary, the results obtained in the course of this study have very important 
implications with respect to the role of PDI in the transport of *NO. Our result show that 
at low concentrations of *NO, PDI was able to denitrosate GSNO, while at the higher 
concentrations, PDI itself may be the target for S-nitrosation and *NO storage. The 
importance of our study becomes evident in the recent study by Uehara and coworkers 
(Uehara et a l, 2006) which showed that PDI-SNO loses its isomerase activity which 
leads to the disregulated protein folding in the ER that promotes neuronal cell death, 
resulting in the development of neurodegenerative disease.
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
73
CHAPTER 3
The role of redox state active site thiols of platelet surface PDI
in S-nitrosothiol consumption
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3.1 Introduction
PDI-mediated RSNO denitrosation activity was established in the previous chapter. 
Here, we will apply these findings to determine the physiological role of PDI 
denitrosation activity under different physiological conditions. This chapter will 
investigate the role of platelet surface PDI in RSNO denitrosation, platelet ROS 
production, platelet aggregation and detection of the dynamic state of PDI active site 
thiols using ICAT-MALDI technology.
3.1.1 Platelet physiology
Platelets were discovered in 1860’s by Max Schultze as blood constituents, and 
characterized in 1880’s by Bizzozero as the first component of the blood to respond and 
adhere to damaged blood vessels (Brewer, 2006). Since then, many discoveries have 
been made about platelet structure and function.
Platelets are derived from the bone marrow cells called megakaryocytes through a 
process of thrombopoiesis regulated by a glycoprotein hormone thrombopoietin. They 
are 1-3 pM in size and during the resting state, platelets are smooth and disc shaped. 
However, upon activation, platelets undergo shape change and develop into a spiny 
spherical form. Platelets are composed of a phospholipid bilayer membrane which 
contains various glycoproteins that serve as receptors for factors that cause platelet 
activation and aggregation (Shapiro, 2000). Platelet cytoskeleton and the microtubular 
system are responsible for maintaining the discoid shape of resting platelets, while the 
nearby dense tubular system, which serves as calcium storage, contains the open
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canalicular system through which secretion of granules occur (Fuse, 1996). Platelet 
cytosol contains dense and alpha granules, mitochondria and lysozymes. The dense 
granules contain ATP and ADP, serotonin and calcium, while alpha granules contain 
adhesive proteins such as fibrinogen, thrombospondin, von Willebrand factor, to name a 
few (Packham, 1994). Upon platelet activation, the granular contents are released into 
the peri-platelet environment thus initiating interactions with other platelets and cells.
3.1.2 Platelet Function
Platelets play a crucial role in vascular hemostasis. Upon vascular injury, platelets 
rapidly aggregate and form a plug which is stabilized by fibrin filaments. Platelet 
activation is caused by the release of granular contents such as collagen, ADP, thrombin, 
fibrinogen, von Willebrand factor (vWF), all of which act synergistically to potentiate 
platelet aggregation (Ware et al., 1987). This results in the interaction between platelet 
glycoprotein (GP) complexes and its ligands, GPIIb/IIIa which bind to vWF and GPIa/IIa 
(a2pi) and collagen. The aggregation of platelets is mediated through the fibrinogen 
receptor GPIIb/IIIa which undergoes a conformational change essential for aggregation 
(Tsuji et al., 1999). The binding of collagen or fibrinogen to their respective receptors 
involves disulfide bond reduction and oxidation (Essex et al., 1999; Lahav et al., 2002). 
The outcome of platelet stimulation with agonists such as collagen or thrombin results in 
hydrolysis of the membrane phospholipids accompanied with the increase in inositol 
1 ,4 ,5 ,-biphosphate (IP3). IP3 accumulation stimulates an increase in intracellular calcium 
levels which essentially modify actin filaments responsible for conformational change of 
platelets (Leopold and Loscalzo, 1995).
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3.1.3 Platelet Surface Protein Disulfide Isomerase
The first report of platelet-surface associated PDI (psPDI) came from the study of Chen 
and coworkers (Chen et al., 1992). Their hypothesis was based on the previous 
observations that intra- and intermolecular thiol-disulfide exchange of thrombospondin 
occurs during the platelet activation. Their findings suggested that there is a PDI-like 
protein activity released upon platelet activation. A few years later, Chen and coworkers 
successfully purified PDI from activated platelets. Their study showed that PDI was 
localized to the platelet plasma membrane, where it can contribute to the modification of 
proteins through its reduction or isomerization activity resulting in cross-linking of 
proteins within the extracellular matrix or cell membranes. A later study by Essex and Li 
(Essex and Li, 1999) showed that psPDI contributes to the activation of fibrinogen 
receptor GPIIb/IIIa through the disulfide bond exchange resulting in platelet aggregation. 
The extension of this study showed that platelet aggregation is mediated though the redox 
state of platelet surface vicinal thiols, such as PDI, with respect to the GPIIb/IIIa 
activation (Essex and Li, 2003).
Concurrently, the role of *NO in mediating platelet activation and aggregation was 
studied. *NO was found to inhibit platelet activation and aggregation though the 
activation of soluble guanylate cyclase (sGC), resulting in an increase in cGMP levels. 
Consequently, platelets exhibited a reduction in cytosolic calcium levels, inhibition of 
cAMP phosphodiesterase and activation of protein kinase G. These events contribute to 
the decrease in platelet aggregation and adhesion and even disaggregation of platelet 
aggregates (Alonso and Radomski, 2003).
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Previous studies have shown that PDI is involved in consumption of S-nitrosothiols 
(RSNO) and disulfide exchange. Therefore, it was only a matter of time to correlate 
these two activities of PDI in elucidating its role in platelet aggregation with respect to 
the presence of RSNO.
3.1.4 Type 2 Diabetes and Platelets
Type 2 diabetes (T2D) is often accompanied with insulin resistance. Insulin resistance 
simply means that cells do not respond to insulin signaling responsible for glucose uptake 
by cells. Therefore, hepatic glucose produced by the body is not successfully internalized 
by skeletal muscle resulting in an increase in circulating glucose levels leading to 
hyperglycemia and hyperinsulinemia. These abnormal physiological conditions affect 
many cellular systems including platelets. As previously described, platelets circulate 
throughout vasculature without adhering to the endothelium unless there is a vascular 
injury. However, diabetic platelets are known to exhibit higher levels of adhesiveness 
and aggregation either spontaneously or by agonist stimulus in vitro. Previous studies 
have shown that T2D platelets are more prone to adhesion to the endothelial cells, 
leukocytes and other platelets resulting in the thrombus formation and atherosclerosis 
(Vinik et al., 2001).
The presence of reactive oxygen species (ROS) has been shown to promote 
hyperaggregability in diabetic platelets resulting in the development of cardiovascular 
disease (Spitaler and Graier., 2002; Sonta et al., 2004). Previous findings from our lab
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(Root PhD Thesis, 2004) showed that upon exposure of platelets to exogenous ROS, a 
decrease in RSNO metabolism was observed as well as enhanced platelet aggregation. 
The main factor of these events is psPDI. Therefore, the observed loss in platelet RSNO 
metabolism was attributed to the oxidation of psPDI active-site thiols due to the increased 
oxidant load.
T2D is accompanied by increased levels of cholesterol, and the current treatment of 
hypercholesteronemia makes use of statins which act as the inhibitors of 3-hydroxy-3 - 
methylglutaryl coenzyme A reductase (HMG-CoA reductase), an enzyme that catalyzes 
the rate limiting step of cholesterol biosynthesis (Maron et al., 2000). Recently, it has 
been observed that statins may have additional vasculoprotective benefits other than 
cholesterol lowering (Collins et al., 2004). The current hypothesis is that statins may 
contain antioxidant properties through inhibition of assembly of NADPH oxidase (NOX). 
NOX is a multimeric protein composed of plasma membrane catalytic subunits p22phox 
and p91pbox, cytosolic regulatory subunits p47phox, p40phox, p67phox and the small G- 
protein Racl or Rac2. Assembly of NOX subunits requires association of Rac GTPase 
which is regulated through its carboxy-terminal geranylgeranylation (Ando et al., 1992). 
Therefore, it was of great interest to establish the relationship between platelets ROS 
levels and the PDI activity with respect to RSNO denitrosation and aggregation.
The Syrian Golden hamster was the animal of choice for development of pre-diabetic 
state. Upon fructose feeding for 7 days, animals develop hyperinsulinemia and
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hyperlipidemia thus representing a viable model for prediabetic, insulin-resistant state 
(Taghibiglou et al., 2 0 0 2 ).
3.1.5 ICAT-MALDITOF Technology
PDI active site thiols direct its activity. Common approaches to analyze thiol redox state 
include spectrophotometric and fluorescence assays (Wright and Viola, 1998) which 
provide quantitative information about average number of modified thiols, but not their 
exact identity. The new approach of quantitative proteomics involves the use of isotope 
coded affinity tag (ICAT) reagents in combination with mass spectrometric analysis to 
detect protein labeling in a complex mixture and accurately quantify the difference in 
protein redox state (Smolka et al., 2001). The ICAT reagent is comprised of three 
functional components. The first one is a thiol-reactive group, followed by the ethylene 
glycol linker that differentiates labeled peptides based on its isotope mass and the biotin 
group which provides an easy purification of tagged peptides by affinity chromatography. 
Therefore, the ICAT approach may be the most suitable way to detect dynamic changes 
in PDI active site thiol status under different conditions.
Therefore, the objectives of this study were to: 1- Determine the kinetic parameters of 
psPDI-mediated GSNO denitrosation; 2- Establish the link between the psPDI 
denitrosation activity, ROS production and platelet aggregation in normal and fructose- 
fed animal model and study the effects of rosuvastatin on normalizing these activities; 4- 
Detect the dynamic redox state of PDI active site thiols using MALDI-TOF technology.
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Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Molecular Probes ,Eugene, Oregon 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Bio-Rad Laboratories Ltd., Mississauga, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario
Amersham Biosciences, Piscataway, New Jersey 
5, 5’-dithiobis(2-nitrobenzoic) acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Dithiothreitol (DTT); Sigma-Aldrich Canada Ltd., Oakville, Ontario
Diphenyleneiodonium chloride (DPI); Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Ethylene diamine tetraacetic acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Fructose; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Goat anti-mouse polyclonal antibody, horseradish peroxidase conjugate;
Stressgen Bioreagents, British Columbia 
Heparin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Imidazole; Sigma-Aldrich Canada Ltd., Oakville, Ontario
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Insulin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Isofluorane; Leamington Animal Clinic, Leamington, Ontario
Monoclonal anti-PDI antibody RL90; Abeam USA, Cambridge, MA 
N-1 -Napthylethylenediamine dihydrochloride;
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
BOC gases, Windsor, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Astra-Zeneca, London, England 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Charles River, Montreal, Quebec 
Bio-Rad Laboratories Ltd., Mississauga, Ontario 
Tetrazolium 4-([3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-l,3-benzene 
disulfonate sodium salt); Roche Diagnostics, Indianapolis, Indiana










Sodium phosphate monobasic: 
Sodium phosphate dibasic; 
Sulfanilamide;
Syrian Golden Hamster; 
TEMED;
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3.2.2 Equipment
Agilent 8453 UV-VIS spectrophotometer;
(Agilent Technologie Canada Inc, Mississauga, Ontario)
Beckman J2-HS Centrifuge;
(Beckman Coulter Canada Inc., Mississauga, Ontario)
BioRad Biologic Work Station;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario)
BioRad Fraction Collector Model 2110;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario)
Hemocytometer;
(Reichert Co, Buffalo, NY)
ISO-NO Mark II with WPIMKII Nitric Oxide electrode;
(World Precision Instruments Inc., Sarasota, Florida)
Jouan CR3i Centrifuge;
(Jouan Inc, Winchester, Virginia)
Labconco FreeZone 4.5 Liter Benchtop Freeze Dry Systems;
(Labconco Corporation, Kansas City, Missouri)
MALDI-TOF MS
(DE-pro Voyager, Applied Biosystems, Foster City, California) 
MALDI-TOF MS/MS
(4700 Proteomics Analyzer, Applied Biosystems, Foster City, California) 
Mettler AJ100 Balance;
(Mettler Toledo Canada, Mississauga, Ontario)
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Microtiter 96-well Solid Plate;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Orion Model 420A pH Meter;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Stir Plate 360 Series;
(VWR International, Mississauga, Ontario) 
Vacutainer Blood Collection Needles;
(Becton Dickinson, Mississauga, Ontario)
Vacutainer Blood Collection Tubes, ACD, 2.5 mL draw; 
(Becton Dickinson, Mississauga, Ontario)
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3.3 Experimental Methods 
3.3.1 Preparation of S-nitrosoglutathione
GSNO was prepared as described elsewhere (Sliskovic et a l, 2005). Briefly, after 
determining free thiol concentration in GSH, a stoichiometric amount of acidified NaNC>2 
was added and the reaction was allowed to proceed for 30 minutes at 4°C. After this, the 
pH of the solution was adjusted to 7.4. The NO2 ' contamination was considered 
negligible as detected by the Griess reagent (Munoz-Fuentes et al., 2003). GSNO was 
recrystallized by the slow addition of ice-cold acetone, which removed NO2 ' levels below 
the detection limit of the Griess reagent.
3.3.2 Purification of Protein disulfide isomerase
Recombinant PDI was expressed using pET-28b vector and Escherichia coli BL21 (DE3) 
strain. This plasmid was prepared by Seslija (2005) and was generously donated to our 
lab. pET 28 plasmid encodes for the full human PDI sequence and contains an N- 
terminal His6 tag. Purification of the recombinant PDI was performed using a high 
capacity nickel column, and PDI was eluted using 250 mM imidazole prepared freshly in 
50 mM Tris-HCl, pH 8.0, and collected in 2 mL fractions. The fractions containing PDI 
were pooled together and dialyzed to remove imidazole, followed by the protein 
quantification by the Bradford assay (Bradford, 1976).
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3.3.3 Animal Feeding and Monitoring Protocols
Experiments performed using Golden Syrian Hamsters in the course of this study were 
approved by the University of Windsor Research Ethics and Animal Care Committees 
and in accordance with the CCAC Guide to the Care and Use o f Experimental Animals. 
Hamsters were housed one per cage and given free access to food and water. Initially, 
animals were divided into two groups one of which received water feeding (control) and 
the second one was given 10% fructose. After two weeks of fructose feeding, animals 
were further divided into four groups: i) control with no rosuvastatin, ii) control with 
lOmg/kg of rosuvastatin, iii) fructose fed with no rosuvastatin and iv) fructose fed with 
1 Omg/kg of rosuvastatin. Rosuvastatin was daily prepared in water and administered to 
the animals by oral gavage for 7 days.
3.3.4 Pharamcokinetics of Rosuvastatin in the Syrian Golden Hamster
Rosuvastatin present in the plasma was determined by collecting 200 pL of blood at 1 
hour intervals after the initial administration for 24 hours. These samples were analyzed 
for rosuvastatin content by the reverse-phase high performance liquid chromatography 
with electrospray ionization tandem mass spectrometric detection at AstraZeneca 
(Wilmington, Denver).
3.3.5 Collection of Blood and Platelet preparation
Isofluorane delivered with 1 % oxygen was used to anaesthetize hamsters in an induction 
chamber. Hamsters were then transferred to a heating pad in the supine position and 
fitted with a rodent circuit. After washing the thorax and abdomen with 70%
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isopropanol, hamsters were put to death by exsanguination. Blood was removed from the 
inferior vena cava with 25 3/8 gauge syringe needle and mixed with ACD (acid citrate 
dextrose: 25 g/L trisodium citrate dehydrate, 15 g/L citric acid monohydrate and 20 g/L 
dextrose) at 9:1 ratio.
Platelet suspension was obtained by the method described by Mustard (Mustard et al., 
1989). Platelet rich plasma was obtained by centrifuging the whole blood for 15 minutes 
at 190 x g at 37°C. Platelets were isolated by further centrifugation for 15 minutes at 
2000 x g and 37°C, and washed three times in Tyrode-albumin solution (pH 7.4). The 
first wash contained heparin (2 U/mL) and apyrase (1 U/mL), the second wash contained 
apyrase only, while the third wash contained Tyrode’s solution without apyrase and 
heparin. Platelets were counted using a hemocytometer.
3.3.6 Platelet surface NADPH oxidase Activity
Platelets (100 pL, 108) in Tyrode-albumin solution, obtained from four study groups of 
hamsters were placed in 96 well plates. The reaction mixture contained 25 pM NADPH, 
25 pM ADP and 10 pL of stock tetrazolium 4-([3-(4-iodophenyl)-2-(4-nitrophenyl)-2H- 
5 -tetrazolio]-l,3-benzene disulfonate sodium salt) (WST-1) colorimetric probe. The 
blank mixture did not contain platelets. NOX activity was monitored as the increase in 
absorbance at 430 nm, as the result of formazan formation, species indicative of 
superoxide presence.
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3.3.7 GSNO consumption by platelets
Consumption of GSNO by washed human platelets was accomplished by directly 
monitoring NO accumulation using the Apollo 400 free radical analyzer equipped with a 
Clark type NO electrode. A standard curve was obtained with various GSNO 
concentrations ranging from 0-250 pM and 500 pM CUSO4 (Pfeiffer et al., 1998). 
Washed human platelets were prepared as previously described and the solution 
containing 2 x 106 platelets/mL was added to ACD buffer containing a range of GSNO 
concentration (0-250 pM), followed by time dependant monitoring of PDI-mediated NO 
release.
The role of ps PDI was assessed by preincubating platelets for 30 minutes with 20 pg/mL 
of anti-PDI antibodies and monitoring the release of NO by the addition of 40 pM 
GSNO.
3.3.8 Platelet aggregation studies
A stock solution of washed human platelets was prepared in Tyrode’s buffer at the 
concentration of 10 x 108 platelets/mL. Aggregation of platelets was initiated with 2.5 
pM ADP and monitored at 630 nm for the loss of turbidity using a 96-well plate 
spectrophotometer (Krause et al., 2001).
3.3.9 Platelet cGMP measurements
Standard curve for cGMP detection was prepared as per manufacturer’s instruction. 
Briefy, varying cGMP concentrations (2 finol-512 frnol) were placed in the 96-well plate 
and incubated with reaction mixture containing cGMP conjugated to horseradish
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peroxidase. Addition of TMB substrate results in a color development which can be 
monitored by measuring absorbance at 630 nm. Similarly, platelet samples (108) 
previously exposed to L-NMMA, an inhibitor of endogenous NO generation, were 
exposed to a known NO donor (Wang et al., 1999) S-nitroso-N-acetlypenicillamine 
(SNAP) (100 pM), for 1 hour at 37°C followed by cGMP measurements as the standards.
3.3.10 Platelet cholesterol measurements
Platelets from healthy volunteers and diabetic patients were prepared as described above. 
Cholesterol standard curve was obtained by incubating varying cholesterol concentrations 
(0-10 pM) with the Amplex Red solutions as per manufacturer’s instructions. Platelets 
(100 pL, 108) were placed in the 96 well plate and the reaction was initiated by the 
addition of Amplex Red (300 pM), HRP (2 U/mL), cholesterol oxidase (2 U/mL) and 
cholesterol esterase (0.2 U/mL). The mixture was incubated for 1 hour at 37°C and the 
end point determination was performed in 96-well fluorescence spectrometer with 530 
nm excitation and 590 nm emission wavelengths. The increase in fluorescence as a result 
of Amplex Red conversion to resorufin due to the presence of H2 O2 that is generated as 
the result of cholesterol oxidation, was used to estimate the amount of cholesterol present 
in each sample, using the cholesterol standard curve.
3.3.11 PDI reduction and spontaneous auto-oxidation
Recombinant PDI (100 pg) was fully reduced by incubation with 5 x molar excess of 
DTT for 2 hours at the room temperature, followed by the chromatographic separation of 
DTT over Sephadex G-25 column in 100 mM phosphate buffer, pH 7.0. Following the
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12separation, PDI was immediately acetone precipitated and labeled with light C-ICAT 
reagent. For auto-oxidation experiments, freshly reduced PDI was incubated for 1 and 3 
hours at the room temperature, acetone precipitated and labeled with heavy 13C-ICAT 
reagent.
3.3.12 ICAT labeling of PDI
19 1 "3Following the labeling of reduced and auto-oxidized PDI with C- and C- ICAT 
reagent for 2 hours at 37°C, two samples were mixed together and subjected to digestion 
with Glu-C for 12 hours at room temperature. Desalting was done using a cation 
exchange cartridge and biotin-labeled peptides were purified using an avidin affinity 
cartridge. After drying of the isolated peptides, the acid cleavable linker was released by 
incubation in the cleavage reagent for 2 hours at 37°C, followed by drying and 
resuspending in 1% formic acid. Prior to MALDI MS analysis, all samples were desalted 
using micro-C 18 ZipTips.
3.3.13 Mass spectrometry analysis
Purified peptides were analyzed by MALDI-TOF MS and MALDI-TOF MS/MS. 
Samples were mixed with matrix in 1:1 ratio (a-cyano-4-hydroxycinnamic acid), spotted 
onto a MALDI target plate and analyzed in reflector mode. Reverse-phase nanoflow 
HPLC system was used for MS/MS analysis thus providing identification of the amino 
acid sequence within the human PDI active site.
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3.4 Results
The animal treatment and blood isolation was performed in collaboration with my 
colleague Shane Miersch. The ICAT-MALDI TOF experiments were performed by 
Anna Kozarova under the supervision of Dr. Otis Vacratsis, Department of Chemistry 
and Biochemistry, University of Windsor.
3.4.1 Kinetic parameters of platelet surface PDI mediated GSNO consumption
Platelet surface PDI-mediated GSNO denitrosation was monitored using an NO- 
electrode. Initially, the electrode was placed in the ACD buffer containing a range of 
GSNO concentrations (10-250 pM) in order to obtain a blank signal. Then, a suspension 
of platelets (108) was added and the release of nitric oxide was monitored over time 
(Figure 3.1 A). The initial rate of NO generation with respect to time, as a function of 
increasing GSNO concentrations displayed saturation kinetics with an apparent Km of 
~22.5 ± 1.2 pM (Figure 3.1 B). In order to establish the contribution of PDI to GSNO 
denitrosation, platelets were preincubated with anti-PDI antibodies for 30 minutes and 
placed in the vial containing GSNO (40 pM). The NO generated with platelets with anti- 
PDI antibodies was -85% lower than platelets alone (Figure 3.2).
























Figure 3.1 Platelet surface PDI mediated GSNO denitrosation.
A. The rate of spontaneous NO generation from GSNO concentrations ranging from 10- 
250 pM was monitored for 120 seconds. At that time platelets (108) in ACD buffer were 
added and the initial rates of NO release were monitored for the kinetic determination.













B. The consumption of GSNO by platelets as shown in the above figure followed 
Michaelis-Menten kinetics as shown by plotting initial rates of »NO release over a range 
of GSNO concentrations (25-250 pM).















Figure 3.2 Inhibition of GSNO denitrosation by PDI antibodies.
Platelet suspension was preincubated with specific PDI antibodies for 30 minutes. 
Denitrosation of GSNO (40 pM) was monitored using an NO-meter in the absence or 
presence of anti-PDI antibodies and represented as the concentration of ’NO generated 
over time (n=4).
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3.4.2 The role of PDI in pre-diabetic platelets of Syrian hamster model
A time course study of plasma rosuvastatin concentration was determined and showed a 
maximum o f 20 nM rosuvastatin at about 4-6 hours following drug administration. The 
increase in rosuvastatin levels at the end of 24 hours was probably due to re-ingestion of 
the drug by coprophagia (Figure 3.3).
Next, we wanted to establish the relationship between four different groups of hamsters 
including i) control (no fructose, no rosuvastatin), ii) drug control (no fructose, 
rosuvastatin), iii) fructose-fed (fructose, no rosuvastatin) and iv) fructose-fed with 
treatment (fructose and rosuvastatin), with respect to PDI denitrosation activity, reactive 
oxygen species generation and platelet aggregation.
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Figure 3.3: Monitoring pharmacokinetics of rosuvastatin in Syrian hamster.
Determination of rosuvastatin levels in plasma was obtained by collection of 200 pL of 
blood at different time intervals over 24 hours from the initial drug administration. 
Plasma concentrations of rosuvastain were analyzed and quantified by the reverse-phase 
HPLC with electrospray ionization tandem mass spectrometric detection.
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Upon fructose feeding, PDI-dependent GSNO denitrosation decreased by ~42% as 
compared to the control group. Administration of rosuvastatin to a control group that did 
not receive fructose resulted in a 20% decrease in the denitrosation activity as compared 
to the control. Interestingly, the fructose fed group that received rosuvastatin treatment 
successfully recovered PDI denitrosation activity almost to the level of control group 
(Figure 3.4 A).
Conversely, while ROS production was relatively low in the control group, the animals 
fed with fructose showed a 60% increase in ROS levels relative to the control. 
Rosuvastatin administration to the control group did not change the ROS levels, while the 
treatment of the fructose fed group decreased and normalized the levels of ROS (Figure
3.4 B)
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Figure 3.4: Monitoring Platelet-surface PDI activity and ROS generation in 
Fructose and Rosuvastatin fed Syrian hamsters
A. Platelets from both control and fructose fed hamsters, with and without lOmg/kg of 
Rosuvastatin were collected and prepared as described in Materials and Methods. PDI 
activity was monitored in the presence of 250 pM GSNO over a 15 minutes time period, 
as a decrease in absorbance at 340 nm, an indicative of S-NO bond cleavage from GSNO. 
Data shown represents the percent difference in rates of *NO release with respect to 
control, with n=13 study samples. P<0.005, * with respect to control, ** fructose fed 
plus Rosuvastatin with respect to fructose fed.





























B. Platelets from both control and fructose fed hamsters, with and without 10 mg/kg of 
Rosuvastatin were collected and prepared as described in Materials and Methods. NOX 
activity was monitored in the presence of 10 pL of WST-1 (stock solution) over a period 
of time. The formation of formazine, indicative of superoxide production was monitored 
as the increase in absorbance at 430 nm. Data shown represents the percent difference in 
rates of formazine formation with respect to control, with n=13 study samples. P<0.005, 
* with respect to control, ** fructose fed plus Rosuvastatin with respect to fructose fed.
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Next, we wanted to correlate the amount of ROS production and PDI-denitrosation 
activity with the ability of platelets to aggregate. Platelet aggregation favors the oxidized 
state of active site thiols of PDI, which are required for integrin-ligand interactions 
(Chapter 1, 1.1.4 b). Upon induction of platelet aggregation with 2.5 pM ADP, the 
fructose-fed group showed an increase of about 90% in aggregation rates (Figures 3.5 A 
and B). This observation was in accordance with diminished PDI denitrosation activity 
and an increase in ROS production. Administration of rosuvastatin to a control group 
showed an increase in aggregation rates of about -20% while fructose fed group that 
received rosuvastatin demonstrated aggregation rates comparable to the control group 
with the rosuvastatin treatment alone.





















Figure 3.5: Effects of Fructose feeding and Rosuvastatin administration on 
Aggregation rates of Syrian hamster platelets
A. Platelets from four study groups of hamsters were collected and prepared as outlined
Q
in Materials and Methods. Aggregation of platelets in Tyrode-albumin solution (10 ), 
was monitored in the absence or presence of 2.5 pM ADP at 630 nm, over 10 minutes 
time period. Data shown represents percent difference in aggregation rates with respect 
to control. n=13 study samples, P<0.005, * with respect to control, ** fructose-fed plus 
Rosuvastatin with respect to fructose-fed.
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B. Actual traces of the above figure. Water-fed, no Rosuvastatin (white triangles); water 
fed, lOmg/kg Rosuvastatin (black triangles); fructose-fed, no Rosuvastatin (white 
diamonds); fructose-fed, lOmg/kg Rosuvastatin (black diamonds).
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3.4.3 Characteristics of diabetic versus normal human platelets
Cholesterol assay and cGMP assay were used to evaluate the levels of cholesterol and 
cGMP in diabetic and normal platelets. Cholesterol assay sensitivity was found to range 
from 1 to 10 pM (Figure 3.6 A), while the cGMP assay was able to detect levels of 2-512 
fmol of cGMP (Figure 3.6 B). Diabetes is often accompanied by increased cholesterol 
levels, which usually result in a variety of complications.
For this purpose, we used platelets from patients with Type 2 diabetes and from healthy 
individuals. First, the platelet samples used for membrane cholesterol estimation were 
exposed to L-NMMA, the inhibitor of nitric oxide synthase, for 5 hours in order to block 
endogenous NO biosynthesis. Next, these platelets were exposed to SNAP (100 pM) for 
1 hour at 37°C and their intracellular cGMP production was measured. Plasma 
membrane cholesterol levels of platelets obtained from healthy subjects were ~2 fold 
lower than T2D (Figure 3.6 C, yellow square). Consequently, the cGMP production 
yielded ~4-fold decrease in T2D platelets as compared to control (Figure 3.6 C, blue 
squares).










Figure 3.6: cGMP and cholesterol levels of normal and diabetic patients.
A. Cholesterol strandard curve with Amplex Red assay. Varying cholesterol 
concentrations (0-10 pM) were used in order to obtain the cholesterol standard curve as 
described in “Experimental Methods”, which was employed for the estimation of 
cholesterol levels in normal and diabetic platelets.















B. cGMP standard curve. cGMP standard curve was obtained using an increasing 
concentrations of cGMP (2 fmol-512 fmol) as described under “Experimental Methods”. 
The levels of cGMP in diabetic and control platelets were estimated using this curve.






















C. cGMP and cholesterol levels from normal and diabetic patients.
Platelets from normal and diabetic patients (n=13) were isolated as described under 
“Experimental Methods”. cGMP assay and cholesterol assay were performed as per 
manufacturer’s instructions. (n=13)
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3.4.4 Determination of PDI active site redox state
The redox state of PDI active site thiols directs its activity. As seen from the above 
studies, under different conditions PDI appears to favor denitrosation, where it requires 
active site to be in its reduced state, or it favors aggregation which involves disulfide 
exchange and consequently oxidized form of PDI active site thiols, as seen with the pre­
diabetic model. Therefore, by monitoring the redox state of PDI active site, it would be 
possible to establish the parameters for an early detection of a disturbed physiological 
state. For that purpose, we used the ICAT thiol labeling approach (Figure 3.7 C) coupled 
to MALDI-TOF to determine different oxidation states of PDI under spontaneous auto­
oxidation. We have observed that fully reduced PDI undergoes a self auto-oxidation in a 
time dependent manner (Figure 3.8). There was a 60% decrease in total thiol 
concentration observed upon 3 hour incubation of fully reduced PDI at room temperature. 
In order to determine which of the PDI active site thiols are susceptible to oxidation, a 
more sensitive approach was utilized.
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Figure 3.7: Schematic of ICAT strategy. A. A schematic model of domain architecture 
of human PDI. Position of all six cysteine residues within the human PDI is highlighted.
B. PDI was separated using SDS-PAGE (10%) and visualized by Coomassie blue stain. 
Lane 1 PDI control purchased from Sigma, lane 2 reduced His-PDI, lane 3 auto-oxidized 
His-PDI. C. Schematic presentation of ICAT labelling protocol.
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Figure 3.8: Auto-oxidation of PDI thiols.
Freshly reduced PDI (1 pM) was incubated with DTNB (1 mM) at zero, 1 and 3 hour 
times. After 3 hour incubation, 60% reduction in thiol concentration was observed. 
Results are presented as % decrease in thiol concentration with respect to fully reduced 
PDI. (n=3)
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The ICAT labeling approach was successful in detecting both PDI active site thiols in a 
and a ’ domain (Figure 3.9). Upon labeling the freshly reduced PDI with 12C-ICAT label, 
the peak at 2147 m/z was detected which represents the labeling of both cysteines in the 
active site a domain FYAPWC3 6GHC39KALAPE. Accordingly, the two cysteines within 
a ’ domain comprising of sequence FYAPWC38 0GHC383KQLAPIWDKLGE were also 
detected at 2916 m/z (Figure 3.9 A).
Once the labeling parameters were obtained, we sought to determine if this approach 
could be used for detecting the redox state of PDI under oxidative conditions. As shown 
in Figure 3.8, PDI undergoes 60% oxidation in 3 hours during the incubation at the room 
temperature. For that purpose, freshly reduced PDI and auto-oxidized PDI were 
incubated with 12C and 13C- ICAT label respectively, and the oxidation state of active site 
thiols in a domain was analyzed. As seen in Figure 3.9 B, there was a 5 fold decrease in 
active site thiols observed in the sample that contained auto-oxidized PDI as calculated 
from the relative intensities of 12C- and 13C- labeled peptides which occurred at 2147 and 
2165 m/z respectively.
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Figure 3.9: Reduced PDI labelled with light 12C-ICAT reagent.
A. Full scan MALDI-TOF spectrum of ICAT-labelled Glu-C digested peptides from 
PDI. All six cysteine residues of PDI were ICAT labelled and detected, the 2147 m/z 
fragment corresponds to the a domain active site with both Cys residues ICAT labelled, 
2916 m/z fragment corresponds to the a ’ domain active site with both Cys residues ICAT 
labelled, fragment at 1178 m/z corresponds to the Cys326 present in the b ’ domain and 
fragments at 1470 m/z, 1728 m/z and 2579 m/z present various mis-cleavages of the 
sequence containing Cys295.












B. MALDI-TOF quantification of reduced (light I2C-ICAT-labelled) and auto-oxidized 
(heavy 13C-ICAT-labelled) PDI following the reverse-phase nano-LC separation. 
Modified peptides corresponding to the a domain active site were detected for reduced 
PDI at L (light ICAT label): 2147 m/z and auto-oxidized PDI at H (heavy ICAT label): 
2165 m/z.
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3.5 Discussion
The initial results of this study are in agreement previous findings that platelets are able 
to metabolize GSNO (Shah et al., 2003). However, we have shown that platelet ability of 
GSNO consumption is due to psPDI. The kinetic study demonstrated that the 
denitrosation activity of platelets follows the saturation kinetics which is indicative of an 
enzyme-mediated process (Figure 3.1 A and B). The participation of PDI was 
established with the use of anti-PDI antibodies and it was observed that platelet 
denitrosation activity was diminished by 80% as compared to the sample without anti- 
PDI antibodies (Figure 3.2). It was previously established the product of RSNO 
denitrosation, nitric oxide, prevents platelet aggregation through a GC/G kinase 
dependent process (Wang et al., 1998). In this pathway, *NO stimulates soluble 
guanylate cyclase resulting in an increase in cGMP that activates G kinase (GK). 
Activation of GK leads to the phosphorylation of thromboxane A2 receptor preventing the 
coupling of the receptor to GTP-binding protein thus inhibiting the activation of 
phospholiapse C, which results in prevention of cellular activation.
Our study suggests another possibility for ’NO-mediated inhibition of platelet activation. 
PDI active site thiols are required for ligand-integrin interaction which leads to the 
platelet aggregation. Therefore, by altering the availability of PDI active site thiols, 
platelet aggregation could be prevented. We are proposing that in the presence of RSNO, 
platelet surface PDI has its active site thiols occupied by performing its denitrosation 
activity thus inhibiting platelet aggregation (Root et al., 2004).
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After the initial parameters for platelet surface PDI-mediated GSNO denitrosation were 
obtained, the next step was to establish the relationship of platelet surface PDI under 
diseased conditions, such as Type 2 Diabetes (T2D). Previous studies have shown that 
platelets of T2D patients contain elevated levels of ROS thus promoting their 
hyperaggregability (Gregg et a l, 2004; Redondo et al., 2005). The present study was 
initiated due to previous observations in our lab that diabetics and an animal model of 
pre-diabetes show a decrease in platelet surface PDI denitrosation activity and 
concomitant increase in the generation of reactive ROS (Root PhD Thesis, 2004). 
Therefore, the hypothesis derived from these independent studies is that the high levels of 
ROS in diabetic platelets could contribute to the oxidation of PDI active site thiols thus 
diminishing its RSNO reductase activity and promoting platelet aggregation.
Rosuvastatin belongs to a group of drugs that inhibit the rate-limiting conversion of 
hydroxymethylglutaryl CoA to mevalonate which is required for the biosynthesis of 
isoprenoids that in turn play a role in assembly of NADPH oxidase subunits responsible 
for ROS production. It was of a great interest to determine the effects of rosuvastatin 
administration to a pre-diabetic animal model in terms of PDI denitrosation activity and 
levels of ROS. Pre-diabetic animal model of T2D using the Syrian Golden hamster was 
previously shown to develop insulin resistance upon fructose feeding of hamsters for 2-3 
weeks (Taghibiglou et a l , 2002).
In agreement with previous observations, our data demonstrated a significant decrease in 
PDI denitrosation activity by -42% upon fructose feeding as compared to the control
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(Figure 3.4 A), and a concomitant increase of 60% in ROS production (Figure 3.4 B). 
Also, the aggregation rates of fructose fed animals displayed a 90% increase relative to 
the control. Therefore, our results suggest that increased ROS levels could potentially be 
responsible for the oxidation of PDI active site thiols resulting in diminished GSNO 
denitrosation accompanied by a concomitant increase in platelet aggregation rates.
The next aim of this study was to establish the effects of short-term rosuvastatin 
treatment on the platelet parameters tested in this study. As shown in Figure 3.4 B, 
rosuvastatin did not affect the levels of ROS when administered to the control group. 
Interestingly, the fructose fed group that received a drug treatment attenuated the 
generation of ROS to the control levels. As for the platelet surface PDI, rosuvastatin 
treatment to the control group of hamsters decreased PDI denitrosation activity by -20% 
(Figure 3.4 A). Previous studies from our lab provided evidence that the interaction of 
PDI with the platelet plasma membrane is likely mediated by hydrophobic interactions, 
rather than electrostatic interactions as previously reported (Raturi PhD Thesis, 2007). 
Therefore, it could be possible that the lowering of cholesterol by rosuvastatin alters the 
hydrophobic character of the platelet plasma membrane in control animals, thus 
diminishing the abundance of the bound enzyme which would account for this -20% loss 
in denitrosation activity. However, treatment of fructose-fed animals with rosuvastatin 
resulted in restoration of psPDI denitrosation activity. Therefore, these results suggest 
that rosuvastatin at nM Cp is effective in decreasing the levels o f ROS in platelets, 
resulting in improved psPDI-catalyzed release of sufficient *NO from GSNO to inhibit 
platelet aggregation. This can be observed from aggregation studies (Figure 3.5 A and B)
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in which rosuvastatin treatment slightly decreased aggregation rates of control animals 
(-20%) and significantly decreased the initial rates of fructose fed animals (-50%). 
Therefore, the overall significance of this study is that rosuvastatin treatment of pre­
diabetic animal model not only contributes to the normalization of platelet ROS 
production and psPDI activities but also improves normal platelet aggregability.
As an extension of the above study, we wanted to determine if the platelet plasma 
membrane cholesterol affects the NO-signaling. T2D is often accompanied with 
hypercholesterolemia (Smith, 2007). The recent observations from our lab suggested that 
NO-diffusion in platelets is blocked by the presence of increased levels of plasma 
membrane cholesterol. We sought to establish the relationship of plasma membrane 
cholesterol and NO-signaling via cGMP pathway in T2D and healthy subjects. As 
previously observed, T2D platelets had ~2-fold higher membrane cholesterol levels as the 
control. Upon probing the same platelet sample for exogenous NO-induced cGMP 
production, T2D platelets displayed a ~4-fold decrease relative to the healthy platelets. 
The data obtained in the course of this study support the proposed hypothesis that 
increased levels of membrane cholesterol may affect the intracellular NO-signaling.
The results obtained in the course of this study emphasize the importance of redox state 
of PDI active site thiols in mediating different enzymatic activities. For example, we 
have shown that in the presence of highly oxidizing conditions such as high ROS, PDI 
favors platelet aggregation and consequently shows a decrease in metabolizing GSNO. 
Therefore, it was of great interest to establish a method for detecting the dynamic state of
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PDI active site thiols, which could potentially be used as a tool to monitor changes of 
individual cysteine residues under various conditions such as T2D. This study was 
initiated by our previous observations that fully reduced PDI undergoes auto-oxidation by 
incubation at the room temperature (Figure 3.8). In order to find out which cysteines 
undergo oxidation, ICAT-MALDI technology was employed. First of all, we wanted to 
determine both active site cysteines could be labeled with ICAT. Incubation of freshly 
reduced PDI with 12C ICAT label and peaks at 2147 m/z and 2916 m/z were detected 
representing the labeling of the active site thiols in a and a’ domain respectively (Figure
3.9 A). Next, in order to determine the auto-oxidation of PDI active site thiols, freshly 
reduced PDI and auto-oxidized PDI were labeled with 12C and 13C ICAT respectively, as 
shown in Figure 3.7 C. Under our experimental conditions, we were able to detect a 5- 
fold decrease upon auto-oxidation of active site thiols of PDI a domain. On the contrary, 
detection of a’ domain active site thiols under auto-oxidation conditions was 
unsuccessful. This could be due to the fact that the active site in a’ domain is more prone 
to oxidation than a domain active site (Lyles and Gilbert, 1994). Overall, this approach 
could still be used for determining the specific redox states of PDI in response to 
different environmental stimuli as well as specific physiological conditions such as T2D.
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CHAPTER 4
The Role of Protein Disulfide Isomerase in Nitric Oxide 
Transport in Red Blood Cells
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4.1 Introduction
Nitric oxide (•NO) is the potent regulator of the vascular tone through the induction of 
vasodilation that enhances blood flow. Previous studies by Stamler and coworkers 
(Stamler et al., 1992) suggested that S-nitroso albumin is the major carrier of *NO in 
blood that in turn can stimulate vasodilation transduced by the small mass S-nitrosothiols 
such as S-nitrosoglutathione (GSNO) with which it exists in equilibrium (Gaston et al., 
1993). Supporting this hypothesis, S-nitrosated form of hemoglobin (Jia et al., 1996) and 
membrane-associated band 3 protein (AE1) (Pawloski et al., 2001) have been detected. 
Therefore, the S-nitrosation mechanism of red blood cell proteins and pathways of *NO 
influx and efflux therein are of great interest to current research.
4.1.1 Red Blood Cells
Human red blood cells (RBCs) are produced by the red bone marrow by the process 
called erythropoiesis and are anucleated cells when mature. The formation of RBCs is 
regulated by the glycoprotein hormone erythropoietin. RBCs resemble biconcave disks 
with a flattened region in the center and dumb-bell shaped cross section, with an average 
size of 6-8 pm.
The main function of RBCs is to carry oxygen throughout the body from the lungs. This 
is achieved with the help of protein hemoglobin (Hb). Hb exists as a tetramer formed 
from two a  and two |3 subunits and contains four heme groups responsible for oxygen 
binding. The iron(II)-dioxygen bond is an essential component of transport and storage
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of molecular oxygen by Hb. The oxygen is bound by the ferrous form of heme through 
the following functional cycle (Shikama and Matsuoka, 2003).
oxygenation




Scheme 4.1: Oxygen binding in hemoglobin
Basically, the autoxidation reaction takes place during reversible oxygen binding to 
deoxy-iron(II) to form oxygenated form of Hb Fe(II)02 resulting in the generation of met- 
Hb and superoxide anion. Ferric iron in met-Hb can not bind molecular oxygen and is 
physiologically inactive. However, RBCs contain an NADH-cytochrome b5 
oxidoreductase known as methemoglobin reductase (Yubisui et al., 1986) which is 
responsible for met-hemoglobin reduction to the ferrous deoxy form. A recent study by 
Shikama and Matsuoka showed that the interaction of different subunits of Hb result in 
different oxygen binding functions (Shikama and Matsouka, 2003). The a  1(32 or a2(31 
interaction results in the cooperative oxygen binding, while the a i p i  or a2(32 interaction 
leads to the stable binding of oxygen with iron(II).
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4.1.2 Ghosts
RBC ghosts are post-hemolytic residues that lack the intracellular elements and are 
mainly made up of the cell membrane. Depending on the hemolysis method used, there 
are two types of hypotonic ghosts, resealed ghosts and white ghosts. Resealed ghosts are 
generally used for incorporation of the solution of interest inside ghosts by a special 
resealing process. This enables studying the transport processes from the extracellular 
medium to the cell interior and structural organization of RBC membranes. Resealed 
ghosts generally have high hemoglobin content since the emphasis is placed on the 
restoration of the original membrane structure, rather than the purity. White ghosts are 
usually free from the visible hemoglobin contamination and lack the intracellular content 
and are widely used for studying the enzymatic properties of the cell membrane 
(Schwoch and Passow, 1973).
The first report of the presence of protein disulfide isomerase (PDI) in ghosts came from 
the study of Alloisio and coworkers (Alloisio et al., 1994). They used western blot 
studies in combination with microscopic studies to identify several residents of the 
endoplasmic reticulum-resident (ER) proteins amongst which were glucose-regulated 
protein GRP78, calreticulin and PDI.
4.1.3 Nitric oxide in Blood
•NO is the important regulator of various physiological conditions (Chapter 1, 1.3). 
Interaction of *NO with specific proteins is essential for the regulation of platelet 
aggregation and vascular smooth muscle relaxation (Hobbs and Ignarro, 1996). The best
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characterized example is the interaction of *NO with the heme moiety of soluble 
guanylate cyclase resulting in its activation and subsequent generation of cGMP (Hobbs, 
1997). In blood, the most physiological example of *NO interaction with a metal 
containing protein is the NO-hemoglobin interaction. »NO can react with ferrous heme 
or with oxy-hemoglobin as follows (Xu et al., 2003):
Fe(II) + NO -> Fe(II)NO (1)
Fe(II)02 + NO —> Fe(III) + N 03' (2)
Equation 1 represents the interaction between ferrous iron and *NO that results in the
7 1 1formation of nitrosyl-heme with the rate constant of 2.6 x 10 M' s' (Cassoly and 
Gibson, 1975). Equation 2 shows interaction of oxy-Hb with *NO resulting in the
7 1 1generation of ferric heme and nitrate with the rate constant of 6-9 x 10 M' s' (Eich et 
al., 1996; Herold et al., 2001). For NO to function, it must be in its free form, meaning 
not bound as it is in nitrosyl-heme. Considering very high hemoglobin concentration 
(-20 mM) it is very difficult to understand how NO can be available to initiate the 
vascular smooth muscle relaxation (Lancaster, 1994), since Hb present in the blood 
would act as a sink for NO available in the environment.
One possibility for solving the puzzle of NO availability in RBCs came from the study of 
Jia and coworkers (Jia et a l, 1996) which identified the existence of S-nitrosated Hb at 
its P-93 cysteine residue. They proposed that Hb could participate in NO transport along 
with oxygen transport. The main reason for this hypothesis came from the observations
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that S-nitrosation of Hb favors the R-state (high oxygen affinity form), while iron 
nitrosylation favors T-state (low oxygen affinity). It has been also observed that the 
intramolecular transfer between HbSNO and HbFe(II)NO is mediated through the oxygen 
saturation-dependent conformational changes (Jia et al., 1996; Stamler et al., 1997; 
McMahon et a l, 2002). Therefore, this model allows the NO captured by the heme as in 
equation 1, to be preserved through the formation of HbSNO, by the reaction involving 
intracellular glutathione (McMahon et al., 2000). The delivery of Hb-bound NO is 
believed to occur through the allosteric regulation by decreasing oxygen saturation, 
which would favor transnitrosation reaction from Hb-SNO to other intracellular thiol 
proteins such as anion exchange protein AE1 (Pawloski et al., 2001).
However, study by Xu and coworkers (Xu et al., 2003) used the whole blood, washed 
RBCs and Hb to investigate the intramolecular transfer to NO from heme to 0-93 cys and 
vice versa, under various oxygen tensions and found no evidence to support the proposed 
mechanism. Therefore, the question of NO transport and availability in RBCs still 
remains unsolved.
Here we investigated the possibility of ghost membrane-associated PDI playing a role in 
NO-efftux from RBCs.
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Biorad Bradford Reagent; 
Bovine Serum Albumin; 
DEAE-Sephacel;
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Bio-Rad Laboratories Ltd., Mississauga, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Diethylamine NONOate (DEANO); Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Dimethyl formamide (DMF); Sigma-Aldrich Canada Ltd., Oakville, Ontario
5, 5’-dithiobis(2-nitrobenzoic) acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario
Dithiothreitol (DTT); 
Eosin isothiocyanate;
Ethylene diamine tetraacetic acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Hemoglobin;
Monoclonal anti-PDI antibody RL90;
Sigma-Aldrich Canada Ltd., Oakville, Ontario 







Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario 
Sigma-Aldrich Canada Ltd., Oakville, Ontario
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Sodium hydroxide; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium nitrite; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium phosphate monobasic: Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium phosphate dibasic; Sigma-Aldrich Canada Ltd., Oakville, Ontario
TEMED; Bio-Rad Laboratories Ltd., Mississauga, Ontario
4.2.2 Equipment
Agilent 8453 UV-VIS spectrophotometer;
(Agilent Technologie Canada Inc, Mississauga, Ontario) 
Beckman J2-HS Centrifuge;
(Beckman Coulter Canada Inc., Mississauga, Ontario) 
BioRad Fraction Collector Model 2110;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario) 
ISO-NO Mark II with WPIMKII Nitric Oxide electrode;
(World Precision Instruments Inc., Sarasota, Florida) 
Jouan CR3i Centrifuge;
(Jouan Inc, Winchester, Virginia)
Labconco FreeZone 4.5 Liter Benchtop Freeze Dry Systems;
(Labconco Corporation, Kansas City, Missouri)
Mettler AJ100 Balance;
(Mettler Toledo Canada, Mississauga, Ontario) 
Microtiter 96-well Solid Plate;
(Thermo Electron Corp. Canada, Burlington, Ontario)
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Mini-Protein II Gel Electrophoresis System;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario) 
Orion Model 420A pH Meter;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Stir Plate 360 Series;
(VWR International, Mississauga, Ontario)
Varian Eclipse Fluorescence Spectrophotometer;
(Varian Canada, Mississauga, Ontario)
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4.3 Experimental Methods
4.3.1 Preparation of Washed Ghosts
Washed ghost were prepared as described by Dodge and coworkers (Dodge et al., 1963). 
Briefly, the whole blood was drawn into ACD buffer at 6:1 ratio and centrifuged at 190 x 
g for 15 minutes in order to separate RBCs from plasma and the buffy coat. RBC were 
subsequently washed 3 times in isotonic phosphate buffer (155 mM NaH2P0 4  and 100 
mM Na2HP0 4 , pH 7.4), and made up as a 50% cell suspension. This 50% cell 
suspension is further diluted 1:10 with isotonic phosphate buffer and stored on ice for 20 
minutes. Sedimentation of RBCs was performed by centrifugation at 4000 x g for 20 
minutes at 4°C, after which a supernatant was removed and sedimented RBCs were 
hemolysed by resuspending the cells 1:15 in hypotonic phosphate buffer (10 mM 
NaH2P0 4  and 6 mM Na2HPC>4 , pH 7.4). Lysed RBCs were left on ice for 30 minutes and 
the ghosts were sedimented by centrifugation at 20 000 x g for 40 minutes at 4°C. 
Hemoglobin was removed by excessive washes in hypotonic buffer. Once prepared, 
ghosts were stored at 4°C and used within two days.
The presence of PDI in ghosts was determined by western blotting using RL90 PDI 
antibodies raised in mouse, and goat anti-mouse-HRP secondary antibodies. The 
visualization was performed using a chemiluminescent HRP substrate.
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4.3.2 Purification of PDI from RBC lysates
PDI was purified from the whole blood using a modified protocol by Hillson (Hillson et 
al., 1984). Whole blood was centrifuged at 190 x g for 15 minutes in order to remove 
plasma and the buffy coat, and subsequently washed 3 times using isotonic phosphate 
buffer. Following the last centrifugation, RBCs were lysed in an ice cold hypotonic 
buffer and centrifuged at 17 000 x g for 45 minutes at 4°C. The resulting supernatant 
was placed in a water bath and the temperature of the lysate was allowed to reach 54°C, 
where it was maintained for 15 minutes. The heat treated lysate was placed on ice to cool 
and centrifuged at 17 000 x g for 45 minutes at 4°C. PDI was further purified by two 
ammonium sulfate precipitations of 55% (35 g ammonium sulfate/100 mL) and 85% (23 
g ammonium sulfate/100 mL). The final pellet obtained after centrifugation at 17 000 x g 
for 30 minutes was dissolved in ~20 mL of 20 mM sodium phosphate buffer, pH 6.3, and 
subsequently dialysed overnight against the same buffer. The dialysed sample was 
loaded onto DEAE-Sephacel column (35 cm x 2 cm) equilibrated with 20 mM sodium 
phosphate buffer, pH 6.3. Bound proteins were eluted using a linear gradient of 0 to 0.7 
M NaCl with a flow rate of 2 mL/min created using a BioRad Biologic Work Station, and 
collected in 2 mL fractions. Collected fractions were tested for PDI activity using a 
modified insulin turbidity assay (Holmgren, 1979). 20 pL of each fraction was placed in 
the 96 well plate with 100 pM insulin and 200 pM DTT in the PDI assay buffer, and the 
increase in turbidity, due to the enzymatic cleavage of insulin, was monitored at 630 nm. 
The purity of the enzyme was assessed by SDS-PAGE and western blotting.
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4.3.3 Synthesis of S-nitroglutathione
S-nitrosoglutathione was prepared as described in Chapter 2.
4.3.4 Synthesis of Dieosin-GSSG
Synthesis o f dieosin-GSSG was performed as described in Raturi and Mutus (Raturi and 
Mutus, 2007). Briefly, synthesis was carried out by incubating GSSG with 10-fold molar 
excess of eosin isothiocyanate in phosphate buffer (100 mM sodium phosphate and 2 mM 
EDTA, pH 8.5) at the room temperature for 6 hours. Unreacted eosin was separated by 
Sephadex G-25 column chromatography. The collected aliquots were tested for the 
maximum increase in fluorescence at 545 nm (A,ex 525 nm) by the addition of DTT (10 
mM), which cleaves the disulfide bond of GSSG thus releasing two GSH molecules with 
eosin attached at the amino terminus resulting in fluorescence increase. Aliquots 
showing a maximum fold increase were pooled together and stored at -80°C. The purity 
of the product was determined by the thin layer chromatography (TLC) in a methanol- 
acetone solvent system (30:70).
4.3.5 Kinetics of Ghost-Dependent Disulfide Reduction
Ghosts (20 pL from 4 mg/mL of protein) were added to the hypotonic phosphate buffer 
containing 2 pM DTT and varying concentrations of dieosin-GSSG (0-2000 nM). 
Increase in fluorescence at 545 nm (A,ex 525 nm), as a result of disulfide bond cleavage of 
GSSG due to the presence of ghosts was monitored as a function of time. Control 
experiment was performed in the absence of ghosts. The actual rate of dieosin-GSSG 
cleavage by ghosts was obtained by subtracting the samples containing ghosts from their
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corresponding controls. All experiments involving disulfide reductase activity were 
performed using 96-well fluorescent plate reader.
4.3.6 Inhibition of Ghost Disulfide Reductase Activity
Inhibition o f the ghosts-dependent disulfide reduction was performed with the use of 
phenylarsine oxide (PAO), which specifically binds to the vicinal thiols (Donoghue et al., 
2000). PAO (200 pM) was incubated with ghosts for 30 minutes at the room 
temperature, and the disulfide reductase assay was performed as described in 4.3.5.
The ghost-mediated disulfide-reductase activity was also monitored in the presence of 
NO donors, GSNO and DEA-NO (25-1000 pM). Previous studies have shown that 
GSNO may S-nitrosate protein thiols through transnitrosation, while DEA-NO 
spontaneously releases NO with a half life of about 2 minutes (Keefer et al., 1996). The 
control did not contain any ghosts. The final rates of disulfide reductase activity were 
obtained by correcting for the corresponding control and are represented as the relative 
fluorescence units with respect to time.
4.3.7 Quantification of Thiols
The total thiol concentration of the ghost suspension was determined with DTNB assay. 
Briefly, the ghost aliquot was incubated with DTNB (1 mM) for 15 minutes at the room 
temperature, followed by the spectrophotometric analysis of characteristic peak which 
develops at 412 nm, due to the formation of nitrothiobenzoate which occurs during 
cleavage of DTNB by thiols. Thiol concentration of ghosts was measured in the presence
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of increasing GSNO or DEA-NO concentration (25-2500 pM), with corresponding 
control which did not contain ghost suspension.
4.3.8 Monitoring Nitric Oxide Release
Ghosts in 1 mL suspension (4 mg/mL of protein) were incubated with DEA-NO (1 mM) 
for 1 hour at the room temperature. The ghost suspension was then centrifuged at 15 000 
x g for 1 0  minutes, followed by 2  washes in hypotonic phosphate buffer to remove 
degradation products of DEA-NO. The pellet obtained after the last centrifugation was 
resuspended in hypotonic phosphate buffer, placed in the vial containing a Clark type NO 
electrode operated though the Apollo 4000 free radical analyzer, and the current was 
monitored for 60 seconds in order to obtain a stable signal. At this time, HgCL (100 pM) 
was added to initiate NO release, and the signal was monitored until saturation was 
established. Control sample of ghosts did not receive DEA-NO treatment.
4.3.9 Biotin Switch Assay
The biotin switch assay was performed as described by Zhang and coworkers (Zhang et 
al., 2005), with minor modifications. Ghosts (4 mg/mL of protein) were incubated with 
GSNO or DEA-NO (1 mM) for 1 hour at the room temperature. Next, N-ethyl 
maleimide (NEM, 50 mM) was added in order to block any free thiols and incubated at 
50°C for 30 minutes. To remove NEM, the ghosts were washed with pre-chilled (-20°C) 
ethanol, incubated at -20°C for 1 hour and centrifuged at 10 000 x g for 10 minutes. The 
supernatant was removed and the pellet was resuspended in the hypotonic phosphate 
buffer. Ascorbate (1 mM) and biotin-NEM (1 mM) were added to the suspension and
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further incubated for 2 hours at the room temperature in dark. Following the incubation, 
the ghosts were precipitated with pre-chilled ethanol to remove excess ascorbate and 
biotin-NEM and resuspended in hypotonic phosphate buffer.
After biotinylation, the samples were mixed with native loading dye and proteins were 
separated by SDS-PAGE (10%) and transferred to a nitrocellulose membrane. Blots 
were developed with strepavidin-HRP (1/100 000 dilution) and with monoclonal RL90 
anti-PDI antibodies (1/10 000 dilution) using goat-anti mouse HRP as the secondary 
antibody.
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4.4 Results
4.4.1 Protein Disulfide Isomerase Associated with RBC ghosts
First, we wanted to detect the presence of PDI in RBC ghosts. Prepared ghosts were 
subjected to extensive washing in hypotonic phosphate buffer, followed by centrifugation 
in order to separate soluble proteins from membrane fraction. As seen from Figure 4.1, 
PDI was detected by western blotting in the supernatant and membrane fraction of ghosts 
(lane 1 and 2). Next, we wanted to determine if PDI was also present in RBC lysates and 
for that purpose, the purification procedure was performed as described in “Experimental 
Methods”. Western blot showed a PDI-reactive band corresponding to the band observed 
with recombinant human PDI (Figure 4.1, lane 4 and 5 respectively).
Once the presence of PDI was established, PDI activity assays were performed as 
described below.
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Figure 4.1: Detection of ghost associated PDI by western blotting
Western blot of 20 jlxL of ghosts shows an anti-PDI reactive band at -58 kDa. Lane 
assignment: 1. 20 pL of ghost pellet; 2. 20 pL of ghost supernatant; 3. recombinant 
human PDI (50 ng); 4. 20 pL of purified PDI from RBC lysates. 5. recombinant human 
PDI (50 ng) (n=3).
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4.4.2 Disulfide Reductase Activity of Ghosts
The assay used for studying disulfide reductase activity of ghosts employed dieosin- 
GSSG. Dieosin-GSSG has fluorescent moieties covalently attached to the two 
N-terminal GSSG residues that results in fluorescence self-quenching and relatively low 
initial fluorescence. However, upon addition of reducing agent such as DTT or in the 
presence of PDI, the disulfide bond of GSSG is cleaved thus resulting in an increase in 
fluorescence (Raturi and Mutus, 2007).
Due to its high sensitivity, this assay was used here for monitoring ghost-associated PDI 
disulfide reductase activity. To this end, increasing concentrations of dieosin-GSSG (25- 
2000 nM) were added to 96-well plate containing 20 pL of ghost suspension with 2 pM 
DTT to a final volume of 100 pL. As Figure 4.2 A shows, there was a continuous 
increase in fluorescence observed with increasing concentration of substrate over time. 
Tha initial rates, subtracted for the corresponding blanks which did not contain ghosts, 
were plotted over increasing dieosin-GSSG concentrations (Figure 4.2 B) and the 
saturation curve reflected the enzyme mediated disulfide reductase activity with a 
estimated Km of~550nM.
















Figure 4.2: Ghost-mediated disulfide reductase activity
A. Concentration dependent increase in disulfide reductase activity. Increasing 
concentrations of Dieosin-GSSG (25-2000 nM) were added to ghosts (20 pL) in the 
presence of 2 pM DTT, and the time dependent increase in fluorescence was monitored 
over time. Traces presented here are corrected for the corresponding control which did 
not contain any ghosts (n=4).















B. Initial rates of disulfide reduction from the above figure as a function of dieosin- 
GSSG concentration (n=4).
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4.4.3 Inhibition of Ghost Disulfide Reductase Activity
The ghost membrane contains various proteins with vicinal thiols that can participate in 
its disulfide reductase activity. The contribution of ghost membrane-associated PDI was 
assessed with the use of known PDI inhibitors, PAO and RL90 PDI-antibody.
PAO is trivalent arsenical that specifically binds to the vicinal thiols. Upon incubation of 
the ghosts with PAO (200 pM, Figure 4.3 black squares) there was a -80% decrease in 
disulfide exchange activity of as compared to ghosts that did not contain PAO (Figure 4.3 
black diamonds). However, ghosts preincubated with RL90 PDI-specific antibodies 
showed a ~15% decrease in disulfide exchange activity as determined by dieosin-GSSG 
assay (Figure 4.4), suggesting that there is a significant contribution of other proteins 
containing vicinal thiols that are present within the ghost membrane that also contribute 
to the disulfide reductase activity observed.
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Figure 4.3: Inhibition of ghost mediated disulfide reductase activity with PAO
The ghosts were incubated in the presence of PAO (200 pM) for 30 minutes at room 
temperature. Dieosin-GSSG (500 nM) was added to the sample without (black 
diamonds) or with PAO (black squares) and the disulfide reductase activity was 
monitored in the presence of DTT (2 pM, n=4).














Figure 4.4: Inhibition of ghost disulfide exchange activity with RL90
The ghosts were preincubated with RL90 specific PDI antibodies for 1 hour at room 
temperature. 20 pL of ghost suspension with or without RL90 was placed in a 96 well 
plate in the presence of dieosin-GSSG (500 nM) and DTT (2 pM) and the increase in 
fluorescence due to the cleavage of GSSG was monitored over time. Rates presented 
here were corrected for the corresponding control that did not contain ghosts (n=3).
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We have previously shown that S-nitrosothiols such as GSNO are capable of inhibiting 
PDI disulfide exchange activity (Root et al., 2004) due to transnitrosation of protein 
thiols. Here, we wanted to establish if ghost disulfide exchange activity could be 
inhibited in the presence of NO donors. Addition of increasing GSNO concentrations 
(25-1000 nM) to the sample containing ghost suspension resulted in the inhibition of 
disulfide exchange activity as shown in Figure 4.5 A.
A similar experiment was performed in the presence of spontaneous NO donor DEA-NO 
which is known to S-nitrosate protein thiols such as PDI (Sliskovic et al., 2005). 
Addition of increasing DEA-NO concentrations resulted in disulfide reductase inhibition 
(Figure 4.5 B) that resembled the one observed with GSNO, suggesting that regardless of 
the NO donor disulfide exchange activity of ghosts can be inhibited.
Next, we wanted to establish the relationship between observed decrease in disulfide 
reductase activity and total thiol concentration of ghosts. Upon incubation of ghosts with 
increasing concentrations of GSNO (25-2500 nM, Figure 4.6 diamonds) or DEA-NO (25- 
2500 nM, Figure 4.6 squares) a concentration dependent decrease in total thiols was 
observed as determined by the DTNB assay. The thiol inhibition curve resembled the 
results obtained from disulfide reductase activity experiments, indicating that the 
decrease in ghost-mediated disulfide reductase activity was due to the disappearance of 
free thiols.
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Figure 4.5: Inhibition of disulfide reductase activity of ghosts
A. GSNO mediated inhibition of disulfide reductase activity.
Disulfide reductase activity of ghosts (20 pL) was monitored in the presence of 2 pM 
DTT and 500 nM dieosin-GSSG as a function of increasing GSNO concentrations (25 
nM to 1000 nM). The data represented here was obtained by subtracting the initial rates 
of samples containing ghosts with corresponding control that did not have any ghosts 
present (n=4).


















B. DEA-NO mediated inhibition of disulfide reductase activity.
Disulfide reductase activity of ghosts (20 pL) was monitored in the presence of 2 pM 
DTT and 500 nM dieosin-GSSG as a function of increasing DEA-NO concentrations (25 
nM to 1000 nM). The data represented here was obtained by correcting the initial rates 
of samples containing ghosts with corresponding control that did not have any ghosts 
present (n=4).






O  GSNO 
□  DEANO
3000
Figure 4.6: Thiol content estimation by DTNB assay
Ghosts were incubated in the presence of increasing GSNO (diamond) or DEA-NO 
(square) concentrations (25-2500 nM) for 1 hour at room temperature. Aliquots of these 
samples were taken and further incubated with DTNB (1 mM) for 15 minutes, followed 
by centrifugation at 10000 x g for 10 minutes. The supernatant was removed and the 
absorbance at 412 nm was measured against corresponding controls that did not contain 
ghosts. Data is presented as pM of thiols per mg of protein (n=4).
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
144
4.4.4 S-nitrosation of Ghosts
So far, we have established that ghost membrane-associated PDI contributes to the 
disulfide reductase activity, which can be inhibited in the presence of increasing GSNO 
or DEA-NO concentration accompanied with corresponding decrease in total 
concentration of free thiols. Next, we sought to establish if these observations were due 
to the thiol oxidation of S-nitrosation.
To this end, ghosts exposed to excess DEA-NO and subsequently washed, were placed in 
the 96 well plate and the disulfide reductase activity was monitored in the absence and 
presence o f DTT. As shown in Figure 4.7, ghosts exposed to DEA-NO showed a 
significant decrease in disulfide reductase activity without DTT present. However, upon 
addition of DTT, there was a ~4-fold increase in activity observed. The same sample was 
placed in the vial with immersed NO electrode and the current was observed for 60 
seconds in order to obtain a stable baseline. At this time, HgCE (200 pM) was added to 
phosphate buffer (Figure 4.8, light grey trace) control and ghosts not exposed to DEA- 
NO (Figure 4.8, black trace) resulting in no increase in current, while the concentration 
dependent increase was observed in the presence of DEA-NO treated ghosts (Figure 4.8, 
dark grey trace and dashed line). This observation suggested the formation of S- 
nitrosated proteins occurs within membranes of RBC ghosts.
In order to determine if PDI is one of the potential proteins of S-nitrosation, we 
performed a biotin switch assay. The biotin switch assay is a widely employed method 
for detecting S-nitrosated protein, although it is constantly under development (Jaffrey et
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al., 2001; Martinez-Ruiz and Lamas, 2004; Foster and Stamler, 2004, Zhang et al., 2005). 
Upon exposure of ghosts with excess of GSNO or DEA-NO, the strepavidin reactive 
signal was observed that corresponded to the bands detected for PDI. Control ghosts also 
showed a faint strepavidin-reactive signal which could be due to the partial blocking of 
the free thiols or PDI disulfide bond reduction under our experimental conditions.
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Figure 4.7: Recovery of disulfide reductase activity by DTT
Ghosts (20 pL) were incubated in the presence of DEA-NO as described in 
“Experimental Methods”. The disulfide reductase activity was monitored in the presence 
of 500 nM dieosin-GSSG, using ghost sample without or with DEA-NO exposure and 
with or without DTT (2 pM, n=4).















Figure 4.8: Release of NO from nitrosated ghosts
Ghosts were incubated in the presence of DEA-NO (1 mM) as described in 
“Experimental Methods”. Control (light grey trace) contained hypotonic buffer only. 
Ghosts that were not exposed to DEA-NO treatment are shown in the black trace. DAE- 
NO treated ghosts were added at 100 pL (dark grey trace) or 200 pL (dashed trace) and 
the current was observed for 60 seconds. At that time HgCl2 was added and the current 
was monitored until signal was stabilized (n=3).
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Figure 4.9: Biotin switch assay of ghosts
The biotin switch assay was performed as described in “Experimental Methods”. Left 
blot was probed against biotin using strepavidin-HRP and right blot represents signal due 
to the presence of PDI. Lane 1 contained ghosts only, lane 2 ghosts treated with GSNO 
and lane 3 ghosts treated with DEA-NO (n=3).
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4.5 Discussion
Protein S-nitrosation offers a covenient method for transport of NO. Previous studies (Jia 
et al., 1996) identified Hb-SNO species and AE1-SNO and proposed that NO transfer 
from the heme iron to P-93 cysteine occurs via allosteric regulation due to the oxygen 
tension mediated by intracellular small thiol molecules. The export o f NO from RBCs is 
thought to be mediated by the formation of S-nitroso protein that would result in a series 
of transnitrosation reaction and subsequent export in the form of protein-SNO. The first 
evidence o f ghost membrane-associated PDI came from the study of Alloisio and 
coworkers (Alloisio et al., 1996) but no known function was assigned to it. Here we 
showed, using western blotting, that PDI is not only associated with the ghost membrane 
(Figure 4.1, lane 1) but could also be released from the ghosts by extensive washing 
(Figure 4.1, lane 2) and is present in cytosol of RBCs as well (Figure 4.1, lane 4).
Disulfide reductase activity of ghosts was performed using a sensitive assay that utilize 
dieosin-GSSG probe, which has two eosin molecules attached to the N-terminal of GSSG 
(Raturi and Mutus, 2007). Upon cleavage of disulfide bond of GSSG, the fluorescence 
quenching due to the close proximity o f two eosin molecules is released thus resulting in 
the increase in fluorescence. Ghost membranes displayed an enzyme-mediated disulfide 
reductase activity as seen by the saturation curve constructed form initial rates of 
disulfide cleavage as a function of increasing dieosin-GSSG concentration (Figure 4.2 A 
and B). Treatment of ghosts with the known vicinal thiol inhibitor PAO resulted in -80% 
inhibition confirming that the activity observed is due to proteins that contain vicinal 
thiols that are present in the ghost membranes (Figure 4.3). However, upon addition of
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PDI specific antibodies (RL90) to the ghost suspension, only -30% inhibition in disulfide 
exchange activity was observed (Figure 4.4). The remaining disulfide reductase activity 
initially observed could be due to the presence of other redox active proteins, such as 
glutaredoxin that have also been identified as the resident of ghost membrane (Papov et 
al., 1994).
Previous studies in our lab showed that NO donors such as GSNO could inhibit PDI 
disulfide exchange activity (Root et a l, 2004) thus inhibiting platelet aggregation. Our 
interest in this study was to determine if NO donors like GSNO that participates in 
transnitrosation, or a spontaneous NO donor DEA-NO could inhibit ghost membrane- 
mediated disulfide exchange. Both GSNO and DEA-NO, successfully inhibited ghost 
membrane-mediated disulfide exchange activity (Figure 4.5 A and B respectively) in the 
concentration dependent manner. Next, we wanted to establish the relationship between 
decrease in activity and total protein thiol concentration. To this end, a ghost suspension 
was incubated with increasing GSNO and DEA-NO concentrations and thiols 
quantification was performed using the DTNB assay. There was a concentration 
dependent decrease in total thiols observed with both GSNO and DEA-NO (Figure 4.6) 
that resembled the activity inhibition studies. Results obtained hitherto demonstrated the 
ability of NO donors to inhibit the disulfide exchange activity and decrease the thiol 
concentration in ghost membranes.
Next, we wanted to investigate the possibility of PDI to become S-nitrosated upon 
exposure to the NO donors. To this end, ghosts treated with DEA-NO were tested for
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disulfide reductase activity in the absence or presence of reducing agent. The ghosts 
treated with DEA-NO showed a significant decrease in activity which was recoverable in 
the presence of DTT (Figure 4.7). When the same sample of NO-loaded ghosts was 
placed in the NO-meter, a concentration dependent increase in current was observed upon 
addition of S-NO bond cleaving agent HgCL. Therefore, these findings suggested that 
upon treatment of ghosts with a spontaneous NO donor DEA-NO, the disulfide reductase 
activity inhibition and decrease in the total thiol concentration were most likely due to the 
proteins S-nitrosation rather than the oxidation of thiols. Lastly, the biotin switch assay 
was performed in order to unambiguously determine if PDI could be one of the target 
proteins for S-nitrosation. While PDI protein concentrations were equal between 
different samples loaded (Figure 4. 9, right blot), the biotin label signal corresponding to 
the PDI band was significant in the samples that were exposed to either GSNO or DEA- 
NO. The faint signal observed in the control sample that did not receive any NO 
treatment could be due to the uncertainties of the assay and experimental condition used 
(Zhang et ah, 2005). A recent study by Forrester (Forrester et ah, 2007) showed that 
while ascorbate treatment used to dissociate S-NO bond may generate a false positive 
signal, the use of flash photolysis for S-NO bond dissociation appears to be a better 
approach leading to the improved reproducibility of the assay.
Therefore, based on the findings from this study, we propose the following mechanism 
(Figure 4.10). PDI-bound NO could potentially enter RBCs via membrane-bound PDI, 
resulting in the transfer of NO to the Fe(II) of Hb. Once nitrosyl heme is formed, the 
reaction could proceed in two directions. In reaction 1, during the low oxygen tension,
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intramolecular NO transfer can occur resulting in S-nitrosated 0-93 Cys of Hb (Jia et al.,
1996). This NO moiety could transnitrosate intracellular PDI which in turn could either 
transnitrosate AE1 (Pawloski et al., 2001) or membrane associated PDI. In reaction 2, 
intracellular S-nitrosated PDI could transnitrosate 0-93 Cys of Hb, subsequently leading 
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Figure 4.10: The Role of PDI in NO influx and efflux in RBCs
PDI is represented by a circle, Hb by squares, anion exchanger (AE1) as a triangle and 
NO as blue and red circles.
Therefore, here we propose a novel mechanism for PDI-mediated NO influx and efflux in 
RBCs. PDI appears to be a great target for this particular function since it is widely 
expressed throughout different locations in the RBCs, and we have previously shown that 
PDI proteins can communicate between themselves and participate in transnitrosation and 
denitrosation reactions (Sliskovic et al., 2005).
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CHAPTER 5
Reversible Inhibition of Caspase-3 Activity by Iron(III) 
Potential Role in Physiological Control of Apoptosis
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5.1 Introduction
So far, we have examined the role of PDI with respect to RSNO denitrosation, platelet 
aggregation and redox state of its active site thiols. This chapter will deal with the novel 
activity of PDI and its role in controlling apoptosis.
5.1.1 Apoptosis
Programmed cell death, also known as apoptosis, is a highly regulated process in which 
unwanted cells are eliminated during a regular homeostasis of multicellular organisms 
(Raff, 1998; Jacobson et a l, 1997). Apoptosis is generally accompanied with a series of 
cellular events including DNA fragmentation, membrane blebbing, cell shrinkage and 
disassembly into membrane-enclosed vesicles. Also, the loss of apoptotic regulation is 
found to be closely linked to human diseases including various forms of cancer, ischemic 
damage, neurodegenerative diseases and immune disorders (Nicholson, 1996). Although 
the exact mechanism of apoptosis regulation is not fully understood, it is now recognized 
that the family of proteins called cysteine proteases or caspases play an essential role in 
the apoptotic process.
5.1.2 Caspase-3
Figure 5.1 represents a summary of different roles of caspases in the initiation of 
apoptosis (Grutter, 2002). Currently there are two major recognized pathways of 
apoptosis, extrinsic and intrinsic pathway. The extrinsic pathway is triggered upon a 
ligand binding to the surface receptor resulting in its trimerization and subsequent 
activation of the initiator caspases- 8  or -10. Caspase- 8  or -10 are capable of activating
R e p r o d u c e d  w i th  p e r m i s s i o n  o f  t h e  c o p y r i g h t  o w n e r .  F u r t h e r  r e p r o d u c t i o n  p r o h i b i t e d  w i t h o u t  p e r m i s s i o n .
155
execution caspases-3 and -7, which once activated can perform a series of proteolytic 
events that eventually result in the apoptosis. However, during the cell stress such as 
irreparable genome damage, pharmaceuticals or ionizing radiation, the intrinsic pathway 
is activated and cytochrome c is released from mitochondria, followed by the activation 
of caspase-9 in complex with Apaf-1. Caspase-9 is another candidate for activation of 
execution caspases-3 and -7. Finally, caspases-1 and -2, located in the ER can be 
activated in the presence of calcium under cellular stress, also resulting in caspase-3 and 
-7 activation. Therefore, by controlling caspase-3 activation, it would be possible to gain 










Scheme 5.1 The role of caspases in the major apoptotic pathways (Grutter, 2000)
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Under normal cellular conditions caspase-3 is synthesized as a single chain precursor and 
exists in an inactive zymogen form. Upon oxidative stress, procaspase-3 is activated by 
the cleavage of the N-terminal prodomain peptide at Aspn9 and the conserved Asp296 and 
Asp3 i6 (Scheme 5.2). These proteolytic cleavages result in the formation of a large 
subunit (a  chain) and a small subunit (P chain) (Lord et ah, 2003), leading to the 
assembly of a homodimer of heterodimers which represents the active form of the 
enzyme (Walker et al., 1999).
D119 R179 H237 C28S D296 D316 R341
I 1 _____;_________
1 Small subunit (p chain)
Proteolytic cleavage
• Active siteR179H237C285 R341
Scheme 5.2 Proteolytic activation of caspase-3 (Grutter, 2000).
The activity and the specificity of caspases are determined by the conserved residues 
which are arranged into a specific structural arrangements required for catalysis. They
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consist of Argng, His237 , Cys285 and Arg3 4 i, with the cysteine residue being a catalytic 
nucleophile, while histidine acts as a general base.
Once activated, caspase-3 is responsible for a proteolytic cleavage of a large number of 
substrates containing common Asp-Glu-Val-Asp (DEVD) motif such as PARP (Lazebnik 
et al., 1994), Ul-70 kDa (Song et al., 1996), DNA-PKcs (Waterhouse et al., 1996), PKC 
6  (Emoto et al., 1995), Huntington (Janicke et al., 1996) and SREBP-1 (Na et al., 1997), 
to name a few.
5.1.3 Regulation of caspase-3 activity
Previous in vitro and in vivo studies have shown that the active-site cysteine residue is 
susceptible to oxidative modification which results in caspase-3 inactivation and 
subsequent inhibition of apoptosis. Nitric oxide (NO) can act as a reversible inhibitor of 
caspase-3 activity, by nitrosating its active site cysteine (Li et al., 1997; Kim et al.,
1997). Reactive oxygen species such as hydrogen peroxide (H2 O2) reversibly inhibit 
caspase-3 activity (Borutaite and Brown, 2001). The recent discovery of metal ion- 
dependent regulation of apoptosis suggested new mechanisms for regulating caspase-3 
activation (Perry et al., 1997; Troung-Tran et al., 2000).
Iron is an essential component o f various biochemical processes including cell 
proliferation, electron transfer and detoxification (Crichton and Ward, 1992). 
Intracellular iron trafficking occurs through the cell surface transferrin receptor (TfR) 
(Klausner et al, 1983). While the expression of TfR in healthy cells is low, carcinoma
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cell lines are accompanied with overexpression of the iron receptor (Inoue et al., 1993). 
Consequently, increased iron levels have been observed in various cancer types 
(Toyokuni, 1996), including HL-60 leukaemic cells, human breast cancer cells and 
human neuroblastoma cells as detected by the apoptosis markers amongst which is an 
increased caspase-3 activity. However, there has been no direct evidence of caspase-3 
interaction with iron.
Protein disulfide isomerase (PDI) is a multifunctional enzyme expressed throughout 
various cellular compartments including ER, cell surface, the cytosol and the nucleus (for 
review on PDI localization, see Turano et al, 2002). The main function of PDI is 
isomerization and rearrangement of disulfide bonds (Darby et al., 1994). As described in 
Chapter 1, the active site of PDI contains two vicinal thiols that undergo a redox state 
change during catalysis (Gilbert, 1997). Recent reports suggested that PDI also has a 
zinc (Solovyev and Gilbert, 2004) and copper (Narindrasorasak et al., 2003) binding 
ability through its active site thiols. Since PDI active site also resembles [2Fe-2S]- 
ferrodoxin iron binding domains (Yeh et al., 2000), we speculated that PDI could also 
bind iron. Therefore, we sought to determine the effects of iron on caspase-3 activity and 
the role of PDI on caspase-3 activation.
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5.2 Material and Equipment
5.2.1 Materials
7-Amino-4-methylcoumarin, N-acetyl-L-aspartyl-Lglutamyl-L-valyl-l-aspartic acid 
amide (Ac-DEVD-AMC) Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ammonium persulfate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Biorad Bradford Reagent; Bio-Rad Laboratories Ltd., Mississauga, Ontario
Bovine Serum Albumin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Copper (II) sulfate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Desferoxamine; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Diethylamine NONOate (DEANO); Sigma-Aldrich Canada Ltd., Oakville, Ontario
Dimethyl formamide (DMF); Sigma-Aldrich Canada Ltd., Oakville, Ontario
5 , 5 ’-dithiobis(2 -nitrobenzoic) acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Dithiothreitol (DTT); Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ethylene diamine tetraacetic acid; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ferric Sulfate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Fluoresceine isothiocyanate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Imidazole; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Insulin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Lysozyme; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Neocuproine; Sigma-Aldrich Canada Ltd., Oakville, Ontario
N-ethylmaleimide (NEM) Sigma-Aldrich Canada Ltd., Oakville, Ontario
Ni-Cam™ Resin; Sigma-Aldrich Canada Ltd., Oakville, Ontario
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Oxidized glutathione; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Potassium phosphate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Reduced glutathione; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sephadex G-25; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium chloride; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium dithionate; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium hydroxide; Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium phosphate monobasic: Sigma-Aldrich Canada Ltd., Oakville, Ontario
Sodium phosphate dibasic; Sigma-Aldrich Canada Ltd., Oakville, Ontario
TEMED; Bio-Rad Laboratories Ltd., Mississauga, Ontario
5.2.2 Equipment
Agilent 8453 UV-VIS spectrophotometer;
(Agilent Technologies Canada Inc, Mississauga, Ontario)
Beckman J2-HS Centrifuge;
(Beckman Coulter Canada Inc., Mississauga, Ontario)
BioRad Fraction Collector Model 2110;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario)
ISO-NO Mark II with WPIMKII Nitric Oxide electrode;
(World Precision Instruments Inc., Sarasota, Florida)
Jouan CR3i Centrifuge;
(Jouan Inc, Winchester, Virginia)
Labconco FreeZone 4.5 Liter Benchtop Freeze Dry Systems;
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(Labconco Corporation, Kansas City, Missouri) 
Mettler AJ100 Balance;
(Mettler Toledo Canada, Mississauga, Ontario) 
Microtiter 96-well Solid Plate;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Mini-Protein II Gel Electrophoresis System;
(Bio-Rad Laboratories Ltd., Mississauga, Ontario) 
Orion Model 420A pH Meter;
(Thermo Electron Corp. Canada, Burlington, Ontario) 
Stir Plate 360 Series;
(VWR International, Mississauga, Ontario)
Varian Eclipse Fluorescence Spectrophotometer;
(Varian Canada, Mississauga, Ontario)
Wallac Victor3TM 1420 Multilabel Counter;
(Perkin Elmer, Waltham, Massachusetts)
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5.3 Experimental Methods
5.3.1 Protein Expression and Purification.
PDI was expressed and purified as described in Sliskovic et al (Sliskovic et al., 2005). 
Briefly, TB medium was used to grow E. coli BL21 (DE3) with the expression vector 
pET-2 8 b containing plasmid that encodes for the entire human PDI sequence with the N- 
terminal His6 tag (Pihlajaniemi et a l, 1987). Induction was initiated with 1 mM 
isopropyl (3-D-thiogalactoside and cells were grown for another 4 hours at 37°C. 
Bacterial pellet was lysed with 0.1 mg/ml lysozyme, followed by sonication. Purification 
of PDI was done using Ni-CAM™ HC Resin (Sigma), equilibrated with 50 mM Tris- 
HC1, pH 8.0. PDI was eluted using 250 mM imidazole. The buffer was exchanged by 
dialysis against 0.1 M potassium phosphate buffer, pH 7. Protein quantification and 
purity was preformed using the Bradford assay (Bradford, 1976) and gel electrophoresis 
and western blotting, respectively.
Human active caspase-3 was expressed in E. coli BL21(DE3) with the expression vector 
pET-28b as previously described (Stennicke and Salvesen, 1997). Briefly, cells grown in 
TB medium were induced with 1 mM isopropyl P-D-thiogalactoside and harvested after 6  
hour incubation at 37°C. Purification of caspase-3, protein quantification and purity was 
carried out as described in the above paragraph.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
163
5.3.2 Caspase-3 Activity.
The conditions used for assay of caspase-3 activity are specified in figure legends. 
Caspase-3 activity was evaluated by measuring proteolytic cleavage of fluorogenic 
synthetic substrate Ac-DEVD-AMC. Assay buffer contained 100 mM phosphate buffer, 
pH 7.0, unless stated otherwise. Fluorescence increase due to AMC release was 
monitored using 360 nm excitation and 460 nm emission wavelengths. All caspase-3 
activity experiments were performed using Wallac Victor3™ 1420 Multilabel Counter 
(Perkin Elmer) and Varian Cary Eclipse fluorescence spectrometer.
5.3.3 Preparation of PDI-bound Iron.
PDI (1 mg) was incubated with 5 x molar excess of Fe2(S04)3 for 1 hr at room 
temperature. Following incubation, excess iron was removed over a Sephadex G-25 
column with 100 mM phosphate buffer, pH 7.0. Final PDI concentration was quantified 
using Bradford assay. PDI-Fe was processed immediately for iron determination.
5.3.4 Iron Determination.
Quantification of complexed iron was performed as described by Fish (Fish, 1988). 
Briefly, PDI and PDI-Fe (50 pg) were mixed with 0.25 mL of reagent A (0.6 M HC1 and 
0.142 M KMn0 4 , freshly made) and digested for 2 hrs at 60°C. Following digestion, 
0.05 mL of reagent B (6.5 mM ferrozine, 13.1 mM neocuproine, 2 M ascorbic aid and 5 
M ammonium acetate) was added and the mixture was vortexed to assure for proper 
mixing. After 30 min incubation at room temperature, absorbance was measured at 562
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nm using an Agilent UV-vis spectrophotometer. The standard curve was obtained 
using 1 to 6  pg/ml ferrous sulphate in 10 mM HC1.
5.3.5 Chemical Blocking of PDI thiols.
PDI active site thiols were chemically modified using N-ethyl maleimide and 
phenylarsine oxide. Prior to chemical blocking, PDI (1 mg) was incubated with 5 x 
molar excess DTT for 2 hr at the room temperature to assure full reduction of the active 
site thiols. Excess DTT was removed over Sephadex G-25 using 100 mM phosphate 
buffer, pH 7.0. Reduced PDI was immediately incubated with 5 x molar excess NEM 
and PAO for 2 hr at the room temperature and chromatographed over a Sepadex G-25 
column. Thiol blocking was checked with DTNB assay (Jiang et a l, 1999).
5.3.6 Preparation of oxidized PDI
PDI active site thiols were oxidized as previously described (Raturi et al., 2005). Briefly, 
PDI (10 pM) was incubated with GSSG (10 mM) overnight at 4°C to fully oxidize PDI 
thiols. Excess GSSH was removed using a Sephadex G-25 column in phosphate buffer 
(100 mM, pH 7.0). Oxidized PDI (PDI-SSG) was quantified using the Bradford assay 
and stored at -80°C.
5.3.7 Lysozyme denaturation and refolding
Lysozyme denaturation and refolding was performed as described by Puig and Gilbert 
(Puig and Gilbert, 1994). Briefly, lysozyme (100 mg/ml) reduction and denaturation was 
done in a buffer containing 8  M urea, 130 mM 2-mercaptoethanol and 25 mM Tris-HCl,
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pH 8 .6 ) for 1.5 hours at 37°C. The reaction was stopped by the addition of 0.1 M acetic 
acid, pH 4.0 resulting in a working solution of lysozyme of 200 pM. Refolding of 
lysozyme (5 pM) was performed by means of measuring lysozyme activity as a decrease 
in absorbance at 650 nm using refolding buffer (100 mM HEPES, 5 mM MgCk, 20 mM 
NaCl and 2 mM EDTA, pH 7) and in the presence of PDI (250 nM) and PDI and 
caspase-3 (250 nM and 800 pg/ml, respectively). Lysozyme activities are reported as a 
fold increase in lysozyme refolding with respect to the same molar amount of native 
lysozyme.
5.3.8 PDI disulfide reductase activity
Dieosin-insulin was prepared by insulin (200 pM) with 5 fold molar excess of eosin 
isothiocyanate. Reaction was left with stirring for 4 hours at the room temperature in 
phosphate buffer (100 mM sodium phosphate and 2 mM EDTA, pH 8.5), followed with 
the removal of unreacted eosin by a Sephadex G-25 column. Insulin content was 
determined by the Bradford assay, while eosin was quantified by monitoring the 
absorbance at 525 nm with 8=88000 M '1cm'1. PDI disulfide reductase activity was 
monitored as an increase in fluorescence at 545 nm (kex 525 nm) due to the cleavage of a 
and b insulin chains. Inhibition of PDI-mediated insulin cleavage was performed in the 
presence of increasing caspase-3 concentrations (50-700 pg/ml).
5.3.9 S-nitrosation of caspase-3
S-nitrosated caspase-3 (caspase-3-SNO) was prepared as follows. Casapse-3 (lmg/ml) 
was incubated with the excess of DEA-NO for 1 hour at the room temperature, followed
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by the chromatographic separation using Sephadex G-25 and 100 mM phosphate buffer 
(pH 7.0). The activity of caspase-3-SNO was assessed by Ac-DEVD-AMC fluorescent 
substrate (25 nM) in the absence (blank) and the presence of PDI (2 pM, sample). 
Monitoring of NO release form caspase-3-SNO was performed using an NO-meter.
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5.4 Results
5.4.1 Chelating agent dependent caspase-3 activation
Assay conditions for measuring caspase-3 activity in the literature generally employ 
chelating agents such as EDTA, as well as reducing agent DTT in order to maintain the 
active site cysteine in its reduced form (Karki et al., 2005). We first sought to determine 
the kinetic parameters of recombinant caspase-3 in the presence and absence of chelating 
and reducing agents. As seen in Figure 5.1, EDTA (triangles) totally abolished the need 
for employing reducing agent such as DTT (diamonds) or GSH (squares), suggesting that 
the activation of caspase-3 mainly depends on the presence of contaminating metal ions, 
which could inactivate caspase-3 by interfering with its active site cysteine required for 
the enzymatic activity. In the absence of EDTA (Figure 5.2), DTT (diamonds) was more 
successful in activating caspase-3 that GSH (squares). The apparent Km of caspase-3 
was estimated to be -20 ± 2 pM in the presence of EDTA (± DTT, GSH, Figure 5.1) and 
-15 ± 2 pM in the absence of EDTA (+ DTT, Figure 5.2).






















Figure 5.1: Chelating and reducing agent dependent activation of caspase-3
A. Caspase-3 (25 nM) activity was monitored over 15 min with increasing 
concentrations of Ac-DEVD-AMC, in the presence of EDTA (2 mM, A ), EDTA and 
DTT (2 mM and 1 mM, respectively, 0) and EDTA and GSH/GSSG (2 mM and 1/0.5 
mM, respectively, □). All rates were corrected with corresponding blanks which did not 
contain caspase-3 (n=4). (X,ex. 360 nm, X,em. 460 nm)



















B. Caspase-3 (25 nM) activity was monitored over 15 min with increasing 
concentrations of Ac-DEVD-AMC, in the absence of reducing agent (A ), and in the 
presence of DTT (1 mM, 0) and GSH/GSSG (1/0.5 mM, □). All rates were corrected 
with corresponding blanks which did not contain caspase-3 (n=4).
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5.4.2 Identification of metal ions responsible for caspase-3 inactivation
In order to identify the metal ions responsible for caspase-3 inhibition, the activity of the 
enzyme was measured in the presence of different metal ion chelators. As shown in 
Figure 5.2, besides EDTA, desferoxamine (DFO, 100 pM) was more successful than 
neocuproine in restoring caspase-3 (25 nM) activity. DFO is the metal chelator with the 
highest affinity of Fe(III). Therefore, the results obtained here suggested that iron may be 
responsible for inhibiting caspase-3 activity. To further test this hypothesis, the activity 
of caspase-3 was measured in a metal free buffer prepared in MiliQ water and treated 
with Chelex-100 resin. As expected, caspase-3 was active in the absence of metal free 
ions. Upon addition of 1-100 pM Fe(III) to 25 nM enzyme, ~90% of the initial activity 
was lost. The IC50 estimated for Fe(III) mediated inhibition of caspase-3 was ~7 ± 2 pM 
(Figure 5.3).
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Figure 5.2: Chelating agent dependent activation of caspase-3.
Capsase-3 (25 nM) activity was monitored over 15 minutes in the presence of Ac-DEVD- 
AMC (20 pM). Assay buffer contained 100 mM phosphate, pH 7.0, EDTA (100 pM), 
neocuproine (100 pM), or desferoxamine (100 pM). Final rates were obtained by 
correcting for the blank rates without caspase-3 and represented as the percentage of the 
highest rate (*P=0.01 compared to EDTA, **P=0.001 as compared to phosphate buffer, 
n=4).
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Figure 5.3: Iron dependent inhibition of caspase-3 activation.
Caspase-3 (25 nM) activity was assessed by Ac-DEVD-AMC (20 pM) in the presence of 
increasing iron concentrations (1-100 pM) in the iron-free phosphate buffer (<50 nM as 
established by the iron determination as described under “Experimental Methods”). The 
initial rates were measured over 15 minutes and corrected for the corresponding controls 
without caspase-3. The rates are represented as the percent of caspase-3 without iron 
(n=4).
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5.4.3 The ability of PDI to activate caspase-3
Next, we investigated the possibility of PDI to act as a metal chelator since its active site 
with CXXC motif is similar to [2Fe-2S]-ferrodoxin iron binding domains (Tsukihira et 
al., 1981). To test this hypothesis, caspase-3 (25 nM) was incubated in a phosphate 
buffer (100 mM, pH 7.0) and no detectable activity was observed. To this sample, an 
increasing amounts of PDI (25 nM to 2.5 pM) were added. The result was a PDI- 
dependent increase in caspase-3 activity (Figure 5. 4 A). In a similar experiment, time 
dependent caspase-3 activity was monitored in a phosphate buffer (Figure 5.4 B, black 
diamonds). Addition of DFO (100 pM) gave a rise to an initial rate of 0.3 pM/min 
(Figure 5.4 B, white diamonds). In the presence of PDI (1 pM) the initial rate was ~ 2.5- 
fold larger than observed with DFO alone (Figure 5.4 B, black squares). The rate with 
PDI and DFO (Figure 5.4 B, white squares) was relatively close to the rate with PDI 
only, suggesting that PDI alone was successful in removing contaminating iron. These 
results also suggest that PDI was a better chelator than DFO and raises the possibility that 
DFO bound iron can still bind to the caspase-3 active site to some extent and partially 
inactivate it.
In a further attempt to demonstrate the PDI-mediated activation of caspase-3 was related 
to Fe(III), PDI (1 pM) and caspase-3 (25 nM) were added to a metal free buffer and the 
initial rates of Ac-DEVD-AMC cleavage were monitored as a function of [Fe(III)] (1-100 
pM), Under these conditions, PDI-activated caspase-3 activity decreased by ~80% in an 
[Fe(III)]-dependent manner with an apparent IC5o of ~3 ± 1 pM (Figure 5.4 C).
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Figure 5.4: PDI dependent caspase-3 activation.
A. Initial rates of caspase-3 activation were monitored in the presence of increasing PDI 
concentrations (25-2500 nM), using Ac-DEVD-AMC (20 pM) as a caspase-3 substrate, 
over 15 minutes (inset). Final rates due to presence of PDI were obtained by subtracting 
the blank which contained caspase-3 only (n=4).
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B. The role of PDI (1 pM) dependent caspase-3 (25 nM) activation was measure in the 
presence (white bars) and absence (blank bars) of DFO (100 pM), using Ac-DEVD-AMC 
(20 pM) as a substrate for caspase-3. Traces shown are representative of caspase-3 
activity in phosphate buffer without (black diamonds) or with PDI (black squares), and 
DFO (100 pM) containing buffer without (white diamonds) or with PDI (white squares). 
The initial rates of caspase-3 activation in the phosphate buffer are represented by the 
black bars, and in the presence of DFO by the white bars (inset). (*P=0.001, n=4).
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C. Caspase-3 (25 nM) activity was monitored by Ac-DEVD-AMC (20 pM) in the 
presence of PDI (1 pM) and increasing iron concentrations (1-100 pM). The initial rates 
of caspase- 3  activity were monitored over 15 minutes, and subtracted for the control 
which did not contain caspase-3 (n=4).
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Next we asked if iron-dependent caspase-3 activation was a reversible process. The 
initial rate o f DEVD-AMC cleavage due to a freshly prepared caspase-3 (25 nM) was 
inhibited by the addition of iron (50 pM) (Figure 5.5 A, grey trace), and the activity was 
successfully restored by the addition of DFO (100 pM) in the time dependent manner. 
Similarly, caspase-3 inhibited by the addition of iron, was successfully restored in the 
presence of DTT (1 mM) (Figure 5.5 B, black trace) or PDI (2 mM) (Figure 5.5 B, grey 
trace). These findings prompted us to investigate whether active site thiols are essential 
for PDI-mediated caspase-3 activation.













Figure 5.5: Reversible activation of iron-inhibited caspase-3.
A. Caspase-3 (25 nM) activity in the iron-free phosphate buffer, pH 7.0, was inhibited by 
the addition of iron (50 pM), and followed by the reactivation with DFO (100 pM) (grey 
trace). Blank (black trace) received the same treatment and did not contain any caspase-3 
(n=3).








B. Caspase-3 (25 nM) activity was inhibited by addition of iron (50 pM) (a), followed 
by reactivation by DTT (1 mM) (black trace, b) or PDI (2 pM) (grey trace, c) (n=3).
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5.4.4 The role of PDI active site thiols in caspase-3 activation
Caspase-3 activity was monitored in the presence of oxidized PDI (PDI-SSG). As shown 
in Figure 5 . 6  A, the activity of caspase-3 in the presence of either DTT (diamonds) or 
PDI-SSG (line) was not significantly different from the activity of caspase-3 only 
(asterisk). Addition of DTT (1 mM) to PDI-SSG (1 pM) significantly increased caspase- 
3 activity (triangles). Next, we prepared chemically modified PDI using a thiol specific 
blocker N-ethylmaleimide (NEM). Results obtained demonstrated that modification of 
PDI active site thiols by NEM prevents caspase-3 activation (Figure 5.6 B). In light of 
these results, the ability of native PDI to bind iron was tested. PDI pretreated with iron 
was found to bind ~ 2 moles of iron per mole of active site thiols (Figure 5.7), suggesting 
that PDI-dependent caspase-3 activation is most likely due to the ability of PDI active site 
thiols to coordinate with iron.










Figure 5.6: Active site thiols are essential for caspase 3 activation.
A. Caspase 3 (25 nM) activation was monitored in the presence of oxidized PDI (1 pM) 
with or without DTT (1 mM), using Ac-DEVD-AMC (20 pM) as a substrate. Caspase-3 
(asterisk), caspase-3 and DTT (diamond), caspase-3 and PDI-SSG (black line) and 
caspase-3 and PDI-SSG in the presence of DTT (triangle). PDI-SSG was prepared as 
outlined under “Experimental Methods” (n=3).





B. Caspase-3 (25 nM) activity was monitored in the absence and presence of PDI and 
NEM-blocked PDI (1 pM) over 15 minutes, using Ac-DEVD-AMC (20 pM). NEM- 
blocked PDI was prepared as outlined in “Experimental Methods” (n=4).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
183
& 2.5 -




O 1  "
ll
JD
 ̂ 0.5 -
PDI FePDI control
Figure 5.7: PDI-bouud iron detection.
Iron estimation was performed for the PDI samples without iron (PDI control) and with 
excess iron incubation (PDI-Fe). Assay was carried out as described in “Experimental 
Methods” (n=4).
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5.4.5 The effects of caspase-3 on PDI activity
The effects of caspase-3 on PDI activity was carried out using two different methods. 
PDI refolding activity was monitored using reduced and denatured lysozyme as a 
substrate. In the presence of caspase-3 (800 pg/ml) the PDI ability to refold denatured 
lysozyme decreased -80% as compared to the control (Figure 5.8 A). Next, we used the 
PDI reductase activity by means of monitoring insulin cleavage of FITC labeled insulin 
which results in an increase in fluorescence. As shown in Figure 5.8 B, caspase-3 was 
able to inhibit PDI-mediated insulin cleavage in a concentration dependent manner (50- 
700 pg/ml).


















Figure 5.8: The role of caspase-3 on PDI enzymatic activity.
A. Lysozyme (5 pM) refolding activity was monitored in the presence of PDI only (250 
nM) and PDI and caspase 3 (800 (ig/ml). Presence of caspase 3 decreased the PDI 
refolding activity of lysozyme by ~90% (n=4).














B. Caspase 3 concentration dependent inhibition of PDI insulin disulfide exchange 
activity was monitored in the presence of caspase 3, PDI (25 nM) and eosin-insulin (25 
nM) probe (n=3).
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5.4.6 The role of nitric oxide in caspase-3 activation
S-nitrosation of caspase-3 results in the reversible inhibition of the enzyme. To test the 
possibility of PDI to activate S-nitrosated caspase-3 (caspase-3-SNO), the activity due to 
the cleavage of Ac-DEVD-AMC was monitored in the presence of caspase-3-SNO and 
caspase-3-SNO and PDI. As seen in Figure 5.9 A, PDI was able to increase caspase-3- 
SNO activity by -10 fold. In order to investigate if this activation was due to the NO 
release from caspase-3-SNO, a NO-meter was employed. Control samples containing 
caspase-3 only did not change its signal upon the addition of PDI (Figure 5.9 B, black 
trace). However, when PDI (2.2 pM) was added to the vial containing caspase-3-SNO, 
an increase in current was observed (grey trace), a representative of NO generation.
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Figure 5.9: PDI dependent Caspase-3 activation monitored by DEVD-AMC 
cleavage.
A. Activation of Caspase 3 and nitrosated Caspase 3 (Caspase 3-SNO) (2 pg/ml) was 
monitored in the presence or absence of PDI (2 pM) over time. Fold increase was 
obtained by correcting the PDI/caspase 3 rates with respect to caspase 3 rates (n=4).
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B. Caspase-3-SNO (2 pg/ml) was placed in the vial containing 100 mM phosphate buffer 
(pH 7.0) and the current was measured for 100 seconds. At that time PDI (2.2 pM, grey 
trace) or buffer (black trace) was added and the increase in current reflecting the release 
of NO was monitored until saturation was obtained (n=3).
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5.5 Discussion
The initial experiments of this study dealt with establishing kinetic parameters for 
caspase-3 activity with respect to its fluorogenic substrate Ac-DEVD-AMC. Initial 
findings were unexpected and suggested that caspase-3 activity is mainly dependent on 
the presence of metal chelators, and the presence of reducing agents such as DTT and 
GSH did not result in the change in activity (Figure 5.1 A). Next, we performed a set of 
experiments to determine which metal was responsible for caspase-3 inhibition. For this 
purpose, caspase-3 activity assay was performed in the presence of a non-specific metal 
chelator EDTA, as well as iron and copper specific metal chelators desferoxamine (DFO) 
and neocuproine, respectively. The results obtained showed that the caspase-3 activity 
was restored in the presence of a specific iron(III) chelating agent DFO (Figure 5.2). 
This finding was supported by the additional evidence with iron(III) dependent inhibition 
of caspase-3 activity with IC50 of ~7 ± 2  pM which corresponds to a 90% inhibition of 
the original activity (Figure 5.3).
Activity of caspase-3 was also restored in the presence of PDI in the concentration 
dependent manner (Figure 5.3 A). In addition, PDI appeared to be a better chelating 
agent than DFO in that a 100-fold lower concentration of PDI was able to yield a ~2-fold 
larger activity from fully iron-inactivated caspase-3 (Figure 5.3 B). One possibility for 
this is that the DFO-Fe(III) complex is relatively small and can still interact with the 
caspase-3 active site and partially block its activity. On the other hand, this is not 
possible with a much larger PDI-Fe(III) complex. PDI dependent caspase-3 activation 
was attenuated by the addition of iron (Figure 5.3 C) with an estimated IC50 of ~3 pM.
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The results obtained so far provided a direct evidence of caspase-3 inhibition by Fe(III), 
which supports previous observations that iron chelating agents can induce apoptosis in 
various cancer cell lines (Jiang et al., 2002; Wang et al., 1999).
Up until now, NO and H2 O2 have been shown to reversibly inactivate caspase-3 (Kim et 
al., 1997; Borutaite and Brown, 2001; Tannenbaum and Kim, 2005). In this study, we 
were able to show that iron(III) can also reversibly regulate caspase-3 activity, most 
likely by interacting with active site Cys285 since inactivation is reversible by thiol 
reductant (Figure 5.1 B) as well as iron chelators (Figure 5.1 A). In addition, our data 
does not preclude iron interacting at the allosteric sites elsewhere in the molecule. A role 
of iron(III) in inactivating caspase-3 was established by the effect of iron(III) specific 
chelator DFO on restoring caspase-3 activity (Figure 5.5 A) and by the direct inhibition 
of caspase-3 and PDI-activated caspase-3 (Figures. 5.3 and 5.4 C). The fact that the 
inhibition by iron(III) is reversible with DFO and PDI, suggests that iron does not play a
T O C
role in altering the oxidation state of the active site Cys .
Next, we attempted to establish if PDI active site thiols are required for caspase-3 
activation. Our data demonstrates that either oxidation (Figure 5.6 A) or chemical 
modification (Figure 5.6 B) of PDI active site thiols inhibits PDI-mediated caspase-3 
activation. Previous reports demonstrated that PDI-like proteins such as glutaredoxin are 
able to form iron-sulfur complexes (Lillig et al., 2005). PDI was found to bind iron at 2:1 
iron:cysteine thiol ratio suggesting that PDI most likely binds iron(III) through its active
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site thiols, as it was shown to bind zinc and copper (Narindrasorasak et al,, 2003; 
Solovyov and Gilbert, 2004).
In order to be active, caspase-3 forms a heterodimer (Grutter, 2000). We sought to test 
the possibility of PDI interacting with caspase-3. Caspase-3 was able to inhibit PDI 
lysozyme refolding activity by 90% (Figure 5.8 A) and disulfide reductase activity of 
insulin (Figure 5.8 B) in a concentration dependent manner. These results suggest that 
PDI may be interacting with caspase-3 probably through its active site thiols, since the 
active site is required for both of the PDI activities tested. Although there is also a 
possibility of PDI assisting the folding of caspase-3 heterodimer, since previous studies 
have suggested that PDI requires all of its domains for its chaperone activity (Sun et al., 
2000). Therefore, PDI does not only remove iron(III) but likely keeps caspase-3 active 
site in its reduced state, resulting in improved caspase-3 activity. Lastly, the possibility 
of PDI activating caspase-3-SNO was tested. Previous studied showed that S-nitrosated 
caspase-3 is reversibly inhibited (Kim et al., 1997; Tannenbaum and Kim, 2005), and 
also that PDI is able to denitrosate small molecular weight thiols and S-nitrosated 
proteins (Sliskovic et al., 2005). Therefore, it was of a great interest to test whether PDI 
is able to restore the activity of S-nitrosated caspase-3. The results obtained using a 
fluorogenic caspase-3 substrate demonstrated that PDI was able to reactivate caspase-3- 
SNO (Figure 5.9 A) by removing NO moiety from caspase-3 active site (Figure 5.9 B).
Based on our findings, we are proposing a physiological role for both iron(III) and PDI in 
the modulation of caspase-3 activity and in the process regulating apoptosis. Previous
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studies showed a correlation between cancer cells and increased iron levels due to i) 
increased expression of transferrin receptor (Inoue et al., 1993), ii) increased ferritin (iron 
storage) secretion (Toyokuni, 1996), and iii) ability of desferoxamine to induce apoptosis 
in cancer cells (Crichton and Ward, 1992). Here we show that a potential target of 
iron(III) is caspase-3, a central regulator of apoptosis. Therefore, we propose the 









Scheme 5.3 Proposed mechanism of caspase-3 regulation in cancer cells.
Cells upon becoming cancerous, upregulate transferrin receptor resulting in an increase of 
intracellular iron(III), which subsequently inactivates caspase-3 thus arresting apoptosis.
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In cells that successfully upregulate and secrete PDI, blocking of caspase-3 activity by 
iron(III) could result in re-initiation of apoptosis and cell death. This suggests that 
substances that induce PDI overexpression (Tanaka et al., 2000) could potentially be 
employed as a new anti-cancer therapeutics.
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Conclusions
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Protein disulfide isomerase (PDI) is a multifunctional eukaryotic protein expressed 
throughout the cell. The most studied function of PDI is its ability to participate in 
disulfide bond isomerization of newly synthesized proteins in the endoplasmic reticulum. 
However, recent findings from our lab suggested that cell surface-associated PDI 
mediates nitric oxide (•NO) release from extracellular S-nitrosothiols (RSNO) thus 
participating in the *NO transport across the membrane. *NO is the small signaling 
molecule involved in many cellular processes such as smooth muscle relaxation, 
modulation of neurotransmission, platelet activation, to name a few. The work presented 
here focused on the role of csPDI in mediating *NO regulated processes.
In Chapter 2, we characterized the S-denitrosation activity of PDI using 
S-nitrosoglutathione (GSNO) as a model. The hemoglobin assay provided strong 
evidence that the main product of PDI denitrosation activity is •NO. Based on our 
findings, we proposed a novel catalytic mechanism for PDI-dependent GSNO 
consumption which involves the formation of a nitroxyl disulfide intermediate that 
undergoes a one-electron oxidation resulting in the generation of *NO and dithiyl radical. 
The evidence for generation of thiyl/dithiyl radicals was provided using a specific 
thiyl/dithiyl radical probe. In the presence of excess *NO, PDI becomes an *NO carrier 
via an N2 0 3 -mediated auto-S-nitrosation of its active site thiols (PDI-SNO). This PDI- 
SNO could then be denitrosated by another PDI, suggesting that this enzyme may be 
intimately involved in mediating the »NO influx and efflux across the membrane.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
197
In Chapter 3, we demonstrated the role of platelet csPDI-dependent GSNO consumption 
resulting in *NO generation. Previous studies have shown that platelet csPDI facilitates 
platelet aggregation through its disulfide exchange activity. On the contrary, *NO can 
inhibit platelet aggeration through the GC/PKC pathway. Our study demonstrated that 
platelet GSNO can inhibit platelet aggregation by occupying active site thiols of PDI 
which are required for ligand-integrin disulfide exchange reaction. It has been observed 
that platelets of both diabetic humans and animal model of diabetes have elevated 
reactive oxygen species (ROS) levels that promote platelet aggregation. Our results 
suggested that there is a relationship between increased ROS levels and PDI-regulated 
activities. Platelets obtained from an animal model of pre-diabetes had significantly 
higher ROS levels relative to control, accompanied by diminished PDI denitrosation 
activity and increased platelet aggregation rates. All of the activities monitored were 
successfully restored in the presence of rosuvastatin an HMG-CoA reductase inhibitor, 
suggesting that this drug might have beneficial effects other than the lowering of 
cholesterol. The redox state of PDI active sites directs its catalytic functionality. 
Therefore, the ability to monitor and identify the dynamic changes in redox state of PDI 
active site thiols may provide insight into how this enzyme is regulated. Our results 
demonstrated that ICAT-MALDI technology may be a suitable method for detecting the 
changes in a domain active site thiols, while active site thiols in a ’ domain appears to 
exist mainly in oxidized form.
Chapter 4 investigated the role of ghost-associated PDI in the transport of NO. Currently, 
it is believed that *NO exits red blood cells (RBC) via formation of S-NO proteins such
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
198
as anion transporter (AE1). Our results showed that in the presence of excess *NO, PDI 
disulfide exchange activity and thiols concentration decrease due to formation of PDI- 
SNO. Based on our findings we proposed the PDI-mediated »NO efflux from RBC, 
where the cytosolic PDI could be nitrosated by hemoglobin-SNO and transport the NO 
equivalents to the ghost-associated PDI which, in turn, could exit the RBC and deliver 
NO to nearby cells.
In Chapter 5 we described a novel role of PDI in regulation of apoptosis. Caspase-3 
activity was inhibited in the presence of iron(III), which could be reversed by the addition 
of iron(III) specific chelator desferoxamine or by PDI. PDI was able to activate iron(III) 
inhibited caspase-3 in a concentration dependent manner, most likely through the 
formation of iron-sulfur complexes through its active site thiols. Therefore, our results 
suggest that iron(III) could be a potential inhibitor of apoptosis through caspase-3 
dependent inhibition, with a possibility of recovery through PDI overexpression in cells.
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APPENDIX
A. Buffers
i) Acid Citrate Dextrose (ACD)
25 g/L trisodium citrate dehydrate 
15 g/L citric acid monohydrate 
20 g/L dextrose
ii) Hypotonic Phosphate Buffer
1.38 g/L NaH2P 0 4 
0.943 g/L Na2H P04 
pH 7.4
iii) Isotonic Phosphate Buffer
21.39 g/L NaH2P 0 4 
14.62 g/L Na2H P04 
pH 7.4
iv) Lysis Buffer
100 mM Tris-HCl 
200 mM NaCl 
2 mM EDTA 
100 pg/mL Lysozyme 
50 pg/mL DNase I 
50 pg/mL RNase 
2 mM PMSF 
1% Triton X-100 
pH 8
v) Phosphate Buffered Saline (PBS)
8 g/L NaCl 
1.44 g/L Na2H P04 
0.24 g/L KH2P 0 4




vi) PDI Assay Buffer
14.2 g/LNa2HP04 
0.58 g/L EDTA 
pH 7.0
vii) Terrific Broth (TB)
12 g/L Tryptone 
24 g/L Yeast Extract
9.4 g/L K2HP04
2.0 g/L KH2P 04 
35 mg/L kanamycin 
pH 7.2
viii) Tyrode Buffer
8.0 g/L NaCl 
0.2 g/L KC1
1.0 g/L NaHC03 
0.05 g/L NaH2P 0 4 
0.2 g/L MgCl2 • 6H20  
0.44 g/L CaCl2- 6H20
3.5 g/L bovine serum albumin 
1 g/L dextrose 
pH 7.4
B. Deterimination of thiol using Ellman’s Reagent
All DTBN assays were performed using a stock solution (10 mM) in 100 mM phosphate 
buffer, pH 8.0. Free thiols in the sample were quantified by addition of DTNB to a final 
concentration of 1 mM followed by the absorbance measurements of nitrothiolbenzoate 
anion at 412 nm, using the extinction coefficient o f 13 600 L mol'1 cm'1 (Ellman, 1959).
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C. Griess Assay
A standard curve was constructed by adding 100 pL of increasing sodium nitrite 
concentrations to 100 pL of 4.0 M HC1 and sulfanilic acid (dissolved in 40 mM HC1) 
each. The standards were thoroughly mixed for 10 minutes and 100 pL of N-(-l- 
naphthyl)ethylenediamine dihydrochloride (2 g/L) was added and left to react for 15 
minutes. The absorbance at 540 nm was measured and plotted over the range of sodium 
nitrite concentrations. Unknown nitrite concentrations were determined in the same way 
as the described above.
D. Protein Quantification Using Bradford Assay
A standard curve was generated using 200 pL of Bradford Protein Assay with a series of 
bovine serum albumin concentrations ranging from 0-20 pg/mL in a phosphate buffer, 
pH 7.0 to a final volume of 1 mL. The mixture was allowed to react for 10 minutes at the 
room temperature and the absorbance was measured at 595 nm. Unknown protein 
concentration was determined in the same way, with appropriate dilutions made in order 
to obtain the absorbance within the range of the standard.
E. SDS-Polyacrylamide Gel Electrophoresis
Resolving gel was prepared as follows:
4.0 mL of H2O
3.3 mL of 30 % acrylamide mix
2.5 mL of 1.5 M Tris (pH 8.8)
0.1 mL of 10%SDS
0.1 mL of 10 % ammonium persulfate
0.002 mL of TEMED
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This combination is sufficient for preparation of two gels. The mixture was added to the 
gel casting cassettes and covered with tert-butanol until the gel polymerized.
Next, stacking gel was prepared as follows:
3.4 mL of H2 O
0.83 mL of 30 % acrylamide ix 
0.63 mL of 1.0 M Tris (pH 6.8)
0.05 mL of 10 % SDS
0.05 mL of 10 % ammonium persulfate
0.005 mL of TEMED
This mixture was poured on top of the resolving gel and the lane comb was inserted until 
the stacking gel was polymerized.
Samples were prepared by combining 20 pL of protein sample with 20 pL loading dye 
and heated at 100°C for 5 minutes.
The gel was generally run at 60 V until the sample had passed through the stacking gel 
when the voltage was increased to 120 V.
Staining was performed using a staining solution containing 0.25 g of Coomassie 
Brilliant Blue, 90 mL of methanol: H2O (1:1 v/v) and 10 mL of stock glacial acetic acid, 
for 1 hour at the room temperature.
Destaining was performed in the same solution lacking Coomassie Brilliant Blue dye, 
until background was brought to the minimum.
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